[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1098
1. Szivek JA, Margolis DS, Schnepp AB, Grana WA, Williams SK: Selective cell proliferation can be controlled with CPC particle coatings. J Biomed Mater Res A; 2007 Jun 15;81(4):939-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective cell proliferation can be controlled with CPC particle coatings.
  • Preliminary studies indicated that human endothelial cells proliferated at different rates on different calcium phosphate ceramic (CPC) particles.
  • The goal of this study was to identify CPC surfaces that encourage bone and vascular cell growth, and other surfaces that support chondrocyte growth while inhibiting proliferation of vascular cells.
  • Differences in bone and vascular cell proliferation were observed when using epoxy without embedded CPCs to encourage bone cells, and when three CPCs were tested, which encouraged vascular cell proliferation.
  • One of these (CPC 7) also substantially depressed cartilage cell proliferation.
  • Only one small-diameter crystalline CPC (CPC 2) supported rapid chondrocyte proliferation, and maintained the cartilage cell phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • [Cites] Biomaterials. 2000 Mar;21(5):431-40 [10674807.001]
  • [Cites] J Biomed Mater Res A. 2006 Mar 1;76(3):656-63 [16294324.001]
  • [Cites] Biophys J. 2001 Nov;81(5):2569-79 [11606271.001]
  • [Cites] J Biomed Mater Res. 2002 Apr;60(1):86-93 [11835163.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2002;12(3):209-36 [12449344.001]
  • [Cites] Biomaterials. 2003 Nov;24(26):4761-70 [14530073.001]
  • [Cites] J Biomed Mater Res A. 2004 Jun 1;69(3):373-81 [15127383.001]
  • [Cites] Biomaterials. 2004 Nov;25(26):5781-8 [15147824.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2004 Aug 15;70(2):250-61 [15264307.001]
  • [Cites] Clin Orthop Relat Res. 1980 Jul-Aug;(150):263-70 [7428231.001]
  • [Cites] J Neurophysiol. 1983 Sep;50(3):684-7 [6619913.001]
  • [Cites] J Vasc Surg. 1984 Nov;1(6):757-64 [6436516.001]
  • [Cites] Biochim Biophys Acta. 1986 Sep 4;883(2):173-7 [3091074.001]
  • [Cites] Ann Vasc Surg. 1989 Apr;3(2):146-52 [2765356.001]
  • [Cites] J Appl Biomater. 1993 Summer;4(2):143-52 [10171661.001]
  • [Cites] J Biomed Mater Res. 1995 Mar;29(3):389-401 [7542245.001]
  • [Cites] J Biomed Mater Res. 1996 Fall;33(3):121-32 [8864883.001]
  • [Cites] J Biomed Mater Res. 1997 Jul;36(1):17-28 [9212385.001]
  • [Cites] Clin Orthop Relat Res. 1997 Sep;(342):254-69 [9308548.001]
  • [Cites] J Biomed Mater Res. 1998 Mar 5;39(3):390-7 [9468047.001]
  • [Cites] J Biomed Mater Res. 1999 Spring;48(1):32-5 [10029147.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Feb;28(2):88-96 [10067711.001]
  • [Cites] Osteoarthritis Cartilage. 1999 Jan;7(1):15-28 [10367012.001]
  • [Cites] J Arthroplasty. 1999 Sep;14(6):714-23 [10512444.001]
  • [Cites] Biomaterials. 2005 Jul;26(21):4453-9 [15701374.001]
  • [Cites] J Artif Organs. 2004;7(4):187-93 [15739051.001]
  • [Cites] Tissue Eng. 2005 Jan-Feb;11(1-2):331-9 [15738686.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2005 Apr;73(1):43-53 [15682399.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2006 Nov;79(2):218-28 [16637034.001]
  • [Cites] Tissue Eng. 2000 Aug;6(4):351-9 [10992432.001]
  • (PMID = 17252549.001).
  • [ISSN] 1549-3296
  • [Journal-full-title] Journal of biomedical materials research. Part A
  • [ISO-abbreviation] J Biomed Mater Res A
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000660-04; United States / NIBIB NIH HHS / EB / EB000660-03; United States / NIBIB NIH HHS / EB / R01 EB000660-02; United States / NIBIB NIH HHS / EB / R01 EB000660-03; United States / NIBIB NIH HHS / EB / EB000660-04; United States / NIBIB NIH HHS / EB / R01 EB000660-01; United States / NIBIB NIH HHS / EB / EB000660-01; United States / NIBIB NIH HHS / EB / EB000660-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Proteoglycans; 97Z1WI3NDX / calcium phosphate
  • [Other-IDs] NLM/ NIHMS23605; NLM/ PMC2288747
  •  go-up   go-down


2. Kong L, Zhang Y, Ye ZQ, Liu XQ, Zhao SQ, Wei L, Gao G: CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res; 2007 Jul;35(Web Server issue):W345-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine.
  • We developed a support vector machine-based classifier, named Coding Potential Calculator (CPC), to assess the protein-coding potential of a transcript based on six biologically meaningful sequence features.
  • Tenfold cross-validation on the training dataset and further testing on several large datasets showed that CPC can discriminate coding from noncoding transcripts with high accuracy.
  • Furthermore, CPC also runs an order-of-magnitude faster than a previous state-of-the-art tool and has higher accuracy.
  • We developed a user-friendly web-based interface of CPC at http://cpc.cbi.pku.edu.cn.
  • In addition to predicting the coding potential of the input transcripts, the CPC web server also graphically displays detailed sequence features and additional annotations of the transcript that may facilitate users' further investigation.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):262-7 [10618406.001]
  • [Cites] RNA Biol. 2006 Jan-Mar;3(1):40-8 [17114936.001]
  • [Cites] Bioinformatics. 2001 Oct;17(10):913-9 [11673235.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):919-29 [11733745.001]
  • [Cites] Genome Res. 2003 Jun;13(6B):1273-89 [12819125.001]
  • [Cites] Genome Res. 2003 Jun;13(6B):1478-87 [12819146.001]
  • [Cites] Bioinformatics. 2003 Oct;19 Suppl 2:ii103-12 [14534179.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D138-41 [14681378.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D235-9 [14681402.001]
  • [Cites] Nat Rev Genet. 2004 Apr;5(4):316-23 [15131654.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D121-4 [15608160.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D125-30 [15608161.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D141-6 [15608165.001]
  • [Cites] Bioinformatics. 2005 Jun;21 Suppl 1:i47-56 [15961493.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1559-63 [16141072.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D10-5 [16381823.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D187-91 [16381842.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D257-60 [16381859.001]
  • [Cites] BMC Bioinformatics. 2005;6:291 [16336650.001]
  • [Cites] Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R17-29 [16651366.001]
  • [Cites] BMC Genomics. 2006;7:41 [16515706.001]
  • [Cites] PLoS Genet. 2006 Apr;2(4):e29 [16683024.001]
  • [Cites] PLoS Genet. 2006 Apr;2(4):e62 [16683036.001]
  • [Cites] BMC Bioinformatics. 2006;7:312 [16790052.001]
  • [Cites] Proteins. 2006 Aug 15;64(3):643-51 [16752418.001]
  • [Cites] Brief Bioinform. 2007 Jan;8(1):6-21 [16772268.001]
  • [Cites] Bioinformatics. 2000 Oct;16(10):906-14 [11120680.001]
  • (PMID = 17631615.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC1933232
  •  go-up   go-down


3. Zhu HF, Fitzsimmons K, Khandelwal A, Kranz RG: CPC, a single-repeat R3 MYB, is a negative regulator of anthocyanin biosynthesis in Arabidopsis. Mol Plant; 2009 Jul;2(4):790-802
The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPC, a single-repeat R3 MYB, is a negative regulator of anthocyanin biosynthesis in Arabidopsis.
  • Single-repeat R3 MYB transcription factors like CPC (CAPRICE) are known to play roles in developmental processes such as root hair differentiation and trichome initiation.
  • We show here that CPC is a negative regulator of anthocyanin biosynthesis.
  • In the process of using CPC to test GAL4-dependent driver lines, we observed a repression of anthocyanin synthesis upon GAL4-mediated CPC overexpression.
  • Rather, CPC expression level tightly controls anthocyanin accumulation.
  • Microarray analysis on the whole genome showed that, of 37 000 features tested, 85 genes are repressed greater than three-fold by CPC overexpression.
  • Also, anthocyanin synthesis genes were shown to be down-regulated in 35S::CPC overexpression plants.
  • Transient expression results suggest that CPC competes with the R2R3-MYB transcription factor PAP1/2, which is an activator of anthocyanin biosynthesis genes.
  • This report adds anthocyanin biosynthesis to the set of programs that are under CPC control, indicating that this regulator is not only for developmental programs (e.g. root hairs, trichomes), but can influence anthocyanin pigment synthesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825656.001).
  • [ISSN] 1674-2052
  • [Journal-full-title] Molecular plant
  • [ISO-abbreviation] Mol Plant
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ FJ268773
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Arabidopsis Proteins; 0 / CPC protein, Arabidopsis; 0 / Proto-Oncogene Proteins c-myb
  •  go-up   go-down


Advertisement
4. Shen G, Schluchter WM, Bryant DA: Biogenesis of phycobiliproteins: I. cpcS-I and cpcU mutants of the cyanobacterium Synechococcus sp. PCC 7002 define a heterodimeric phyococyanobilin lyase specific for beta-phycocyanin and allophycocyanin subunits. J Biol Chem; 2008 Mar 21;283(12):7503-12
StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biogenesis of phycobiliproteins: I. cpcS-I and cpcU mutants of the cyanobacterium Synechococcus sp. PCC 7002 define a heterodimeric phyococyanobilin lyase specific for beta-phycocyanin and allophycocyanin subunits.
  • PCC 7002 identified three genes, denoted cpcS-I, cpcU, and cpcV, that were possible candidates to encode phycocyanobilin (PCB) lyases.
  • Single and double mutant strains for cpcS-I and cpcU exhibited slower growth rates, reduced PBP levels, and impaired assembly of phycobilisomes, but a cpcV mutant had no discernable phenotype.
  • A cpcS-I cpcU cpcT triple mutant was nearly devoid of PBP.
  • SDS-PAGE and mass spectrometry demonstrated that the cpcS-I and cpcU mutants produced an altered form of the phycocyanin (PC) beta subunit, which had a mass approximately 588 Da smaller than the wild-type protein.
  • The modified PC from the cpcS-I, cpcU, and cpcS-I cpcU mutant strains was purified, and biochemical analyses showed that Cys-153 of CpcB carried a PCB chromophore but Cys-82 did not.
  • These results show that both CpcS-I and CpcU are required for covalent attachment of PCB to Cys-82 of the PC beta subunit in this cyanobacterium.
  • Suggesting that CpcS-I and CpcU are also required for attachment of PCB to allophycocyanin subunits in vivo, allophycocyanin levels were significantly reduced in all but the CpcV-less strain.
  • We conclude that the maturation of PBP in vivo depends on three PCB lyases: CpcE-CpcF, CpcS-I-CpcU, and CpcT.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199754.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU145731/ EU145732/ EU145733
  • [Grant] United States / NIGMS NIH HHS / GM / GM-31625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Phycobilisomes; 0 / allophycocyanin; 11016-15-2 / Phycocyanin; EC 4.- / Lyases; EC 4.4.- / phycocyanin alpha-subunit phycocyanobilin lyase
  •  go-up   go-down


5. Puska PM, Tarkkanen AH: Transscleral red laser cyclophotocoagulation for the treatment of therapy-resistant inflammatory glaucoma. Eur J Ophthalmol; 2007 Jul-Aug;17:550-553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate in a retrospective study the long-term usefulness of red 647 nm krypton and 670 nm diode laser for transscleral contact cyclophotocoagulation (CPC) in the treatment of therapy-resistant inflammatory glaucoma.
  • RESULTS: The mean preoperative intraocular pressure (IOP) of 35.68.1 mmHg fell to 6-21 mmHg level in 75% after one or repeated CPC.
  • CONCLUSIONS: Transscleral CPC using red 647 nm krypton or 670 nm diode laser is an effective and well-tolerated procedure for the treatment of therapy-resistant inflammatory glaucoma in adults.
  • CPC can be considered before incisional antiglaucoma surgery with a shunt or antimetabolites is undertaken.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221549.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Zhao KH, Zhang J, Tu JM, Böhm S, Plöscher M, Eichacker L, Bubenzer C, Scheer H, Wang X, Zhou M: Lyase activities of CpcS- and CpcT-like proteins from Nostoc PCC7120 and sequential reconstitution of binding sites of phycoerythrocyanin and phycocyanin beta-subunits. J Biol Chem; 2007 Nov 23;282(47):34093-103
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lyase activities of CpcS- and CpcT-like proteins from Nostoc PCC7120 and sequential reconstitution of binding sites of phycoerythrocyanin and phycocyanin beta-subunits.
  • Genes all5292 (cpcS2) and alr0617 (cpcS1) in the cyanobacterium Nostoc PCC7120 are homologous to the biliprotein lyase cpcS, and genes all5339 (cpcT1) and alr0647 (cpcT2) are homologous to the lyase cpcT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895251.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Multiprotein Complexes; 0 / Phycobilins; 0 / Protein Subunits; 0 / Recombinant Proteins; 0 / phycoerythrocyanin; 11016-15-2 / Phycocyanin; EC 4.- / Lyases
  •  go-up   go-down


7. Liu Y, Liu M, Ren P: [Drug delivery of CPC/cisplatin complex in vitro and its ability to repair bone defect and eliminate tumor in vivo]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Oct;34(10):991-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug delivery of CPC/cisplatin complex in vitro and its ability to repair bone defect and eliminate tumor in vivo].
  • OBJECTIVE: To explore the best mass ratio of calcium phosphate cement (CPC)/cisplatin complex filling and to repair bone defect caused by tumor resection.
  • We implanted CPC and CPC/cisplatin complex to observe the repair of bone defect and the inhibition of tumor in vivo.
  • RESULTS: CPC containing 0.1% approximately 0.2% cisplatin not only repaired the bone defect in rabbits but also eliminated osteosarcoma in rats.
  • CONCLUSION: CPC containing 0.1% approximately 0.2% cisplatin can repair bone defect and eliminate tumor without influencing the prosthetic precess.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893250.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Bone Cements; 0 / Bone Substitutes; 0 / Calcium Phosphates; 0 / Delayed-Action Preparations; 701EKV9RMN / calcium phosphate, monobasic, anhydrous; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Maresca TJ, Groen AC, Gatlin JC, Ohi R, Mitchison TJ, Salmon ED: Spindle assembly in the absence of a RanGTP gradient requires localized CPC activity. Curr Biol; 2009 Jul 28;19(14):1210-5
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle assembly in the absence of a RanGTP gradient requires localized CPC activity.
  • Gradient-free spindle assembly occurred around sperm nuclei but not around chromatin-coated beads and required the chromosomal passenger complex (CPC).
  • Artificial enrichment of CPC activity within hybrid bead arrays containing both immobilized chromatin and the CPC supported local microtubule assembly even in the absence of a RanGTP gradient.
  • We conclude that RanGTP and the CPC constitute the two major molecular signals that spatially promote microtubule polymerization around chromatin.
  • Furthermore, we hypothesize that the two signals mainly originate from discreet physical sites on the chromosomes to localize microtubule assembly around chromatin: a RanGTP signal from any chromatin and a CPC-dependent signal predominantly generated from centromeric chromatin.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2002 Oct;13(10):3614-26 [12388761.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2452-6 [11923538.001]
  • [Cites] J Gen Physiol. 1967 Jul;50(6):Suppl:259-92 [6058222.001]
  • [Cites] J Cell Biol. 1984 May;98(5):1730-45 [6725396.001]
  • [Cites] J Cell Biol. 1984 Jul;99(1 Pt 2):47s-54s [6235234.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):755-65 [4030893.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):2053-67 [3316246.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5732-44 [7988569.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):420-5 [8684481.001]
  • [Cites] Curr Biol. 1999 May 6;9(9):481-4 [10322113.001]
  • [Cites] Science. 1999 May 21;284(5418):1359-62 [10334991.001]
  • [Cites] Nature. 1999 Jul 8;400(6740):178-81 [10408446.001]
  • [Cites] Curr Biol. 2006 Mar 7;16(5):536-41 [16527751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4493-8 [16537398.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):697-701 [16572176.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):833-7 [16769825.001]
  • [Cites] Dev Cell. 2007 Jan;12(1):31-43 [17199039.001]
  • [Cites] Mol Biol Cell. 2008 May;19(5):1873-82 [18287525.001]
  • [Cites] Development. 2008 Oct;135(19):3239-46 [18755775.001]
  • [Cites] Biochemistry. 1995 Jan 17;34(2):639-47 [7819259.001]
  • [Cites] Cell. 2001 Jan 12;104(1):83-93 [11163242.001]
  • [Cites] Cell. 2001 Jan 12;104(1):95-106 [11163243.001]
  • [Cites] Science. 2001 Jan 26;291(5504):653-6 [11229403.001]
  • [Cites] Science. 2001 May 25;292(5521):1540-3 [11375490.001]
  • [Cites] J Cell Biol. 2001 Jun 11;153(6):1209-26 [11402065.001]
  • [Cites] Cell. 2004 Jul 23;118(2):187-202 [15260989.001]
  • (PMID = 19540121.001).
  • [ISSN] 1879-0445
  • [Journal-full-title] Current biology : CB
  • [ISO-abbreviation] Curr. Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM024364-25; United States / NIGMS NIH HHS / GM / F32GM080049; United States / NIGMS NIH HHS / GM / F32 GM080049; United States / NIGMS NIH HHS / GM / R01 GM024364-25; United States / NIGMS NIH HHS / GM / R37 GM024364; United States / NCI NIH HHS / CA / CA078048-09; United States / NIGMS NIH HHS / GM / R01 GM024364; United States / NIGMS NIH HHS / GM / GM24364; United States / NCI NIH HHS / CA / P01 CA078048
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin; 0 / Multiprotein Complexes; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.6.5.2 / ran GTP-Binding Protein
  • [Other-IDs] NLM/ NIHMS128828; NLM/ PMC2752711
  •  go-up   go-down


9. Lebeau B: [Small cell lung cancer (CPC). Second line treatment]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S205-16S208
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell lung cancer (CPC). Second line treatment].
  • [Transliterated title] Les cancers à petites cellules (CPC). Quel traitement de deuxième ligne?
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268359.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 20
  •  go-up   go-down


10. Pujol JL, Quantin X, Jacot W, Serre A, Fayolle V: [Small cell lung cancer (CPC). Small cell bronchial carcinoma: therapeutic management]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S198-16S204
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell lung cancer (CPC). Small cell bronchial carcinoma: therapeutic management].
  • [Transliterated title] Les cancers à petites cellules (CPC). Prise en charge thérapeutique.
  • Small cell bronchial carcinoma holds a prominent position among malignant tumours on account of its high incidence and the problems of its treatment.
  • Small cell bronchial carcinoma is often metastatic at the time of diagnosis and should be considered an actual or potential systemic disease.
  • [MeSH-major] Carcinoma, Bronchogenic / therapy. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268358.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


11. Ramos HR: View from Argentina: chest pain centers progress. Crit Pathw Cardiol; 2005 Dec;4(4):187-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] View from Argentina: chest pain centers progress.
  • The prevalence of acute coronary syndromes (ACS) throughout the world has been a stimulus for the development of chest pain centers beyond the United States, where the concept first emerged.
  • The rationale for the development of chest pain centers in Argentina includes the abundance of ACS and the objective of optimizing healthcare delivery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340208.001).
  • [ISSN] 1535-2811
  • [Journal-full-title] Critical pathways in cardiology
  • [ISO-abbreviation] Crit Pathw Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Tsukahara T, Tanno Y, Watanabe Y: Phosphorylation of the CPC by Cdk1 promotes chromosome bi-orientation. Nature; 2010 Oct 7;467(7316):719-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation of the CPC by Cdk1 promotes chromosome bi-orientation.
  • To achieve chromosome bi-orientation at prometaphase, the chromosomal passenger complex (CPC), composed of catalytic kinase Aurora B and regulatory components (INCENP, Survivin and Borealin), must be localized to centromeres to phosphorylate kinetochore substrates.
  • Although the CPC dynamically changes the subcellular localization, the regulation of centromere targeting is largely unknown.
  • Preventing Survivin phosphorylation impairs centromere CPC targeting as well as chromosome bi-orientation, whereas phosphomimetic Survivin suppresses the bi-orientation defect in the cyclin B mutant.
  • Survivin phosphorylation promotes direct binding with shugoshin, which we now define as a conserved centromeric adaptor of the CPC.
  • Thus, our study resolves the conserved mechanisms of CPC targeting to centromeres, highlighting a key role of Cdk1-cyclin B in chromosome bi-orientation.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739936.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Bir1 protein, S pombe; 0 / CDCA8 protein, human; 0 / Carrier Proteins; 0 / Cdc13 protein, S pombe; 0 / Cell Cycle Proteins; 0 / Chromosomal Proteins, Non-Histone; 0 / Cyclin B; 0 / INCENP protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Multiprotein Complexes; 0 / Nbl1 protein, S pombe; 0 / SGOL1 protein, human; 0 / SGOL2 protein, human; 0 / Schizosaccharomyces pombe Proteins; 0 / Sgo2 protein, S pombe; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / ark1 protein, S pombe; EC 2.7.11.22 / CDC2 Protein Kinase; EC 2.7.11.22 / cdc2 protein, S pombe
  •  go-up   go-down


13. Dagang G, Haoliang S, Kewei X, Yong H: Long-term variations in mechanical properties and in vivo degradability of CPC/PLGA composite. J Biomed Mater Res B Appl Biomater; 2007 Aug;82(2):533-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term variations in mechanical properties and in vivo degradability of CPC/PLGA composite.
  • A new type of bone cement composite was successfully achieved by mixing degradable biosecure polylactic-co-glycolic acid (PLGA) fibers with high initial strength calcium phosphate cement (CPC).
  • So this bone cement composite containing fibers and the controlling group could be termed as CPC/PLGA composite and pure CPC or fiber-free group, respectively.
  • In this study, we had investigated mechanical properties and microstructures of the CPC/PLGA composite immersed in 0.9% saline solution for different time and its in vivo degradation behaviors after implanting in rabbit muscle and femur bone, respectively.
  • Results showed that the incorporation of the degradable fibers not only greatly increased the initial toughness and flexural strength of the CPC/PLGA composite but also significantly improved its later osteo-conduction as well as degradation rate.
  • The rabbit muscle implant tests showed that the weight loss ratio of the CPC/PLGA composite increased by 41.03% as compared to the pure CPC.
  • And the rabbit femur implant tests showed that the composite exhibits outstanding biocompatibility and bioactivity and more excellent osteoconduction and degradability than the pure CPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318820.001).
  • [ISSN] 1552-4973
  • [Journal-full-title] Journal of biomedical materials research. Part B, Applied biomaterials
  • [ISO-abbreviation] J. Biomed. Mater. Res. Part B Appl. Biomater.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements; 0 / Calcium Phosphates; 0 / Solutions; 0 / calcium phosphate polylactic-co-glycolic acid composite; 26009-03-0 / Polyglycolic Acid
  •  go-up   go-down


14. Zhou N, Wang J, Liu C, Fan C, Zhang Q, Xue F, Zhang J: [Clinical application of bioactive CPC loading rhBMP-2 in repairing bone defects]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Mar;23(3):257-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of bioactive CPC loading rhBMP-2 in repairing bone defects].
  • OBJECTIVE: To investigate the clinical application of self-setting CPC loading rhBMP-2 for repair of bone defects and to evaluate the clinical effect and safety.
  • METHODS: From June 2006 to September 2007, 112 bone defects patients were treated by CPC loading rhBMP-2 (rhBMP-2/CPC group) or CPC (control group).
  • In the rhBMP-2/CPC group, 49 patients included 31 males and 18 females, aging from 16 to 68 years with an average of 45.6 years.
  • All defects were repaired with rhBMP-2/CPC (2-5 g) and CPC (2-50 g) in the rhBMP-2/CPC group and the control group, respectively.
  • Incisions oozing light yellow fluids were found in 4 patients (control group in 1, rhBMP-2/CPC group in 3), and then healed through dressing changes and taking glucocorticoid.
  • CONCLUSION: Repairing bone defects with rhBMP-2/CPC is safe and effective.
  • Using rhBMP-2/CPC is a promising therapy to deal with bone defects.

  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19366127.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Morphogenetic Protein 2; 0 / Bone Substitutes; 0 / Recombinant Proteins
  •  go-up   go-down


15. Liu YN, Liu M, Ren PY: [Drug delivery of CPC/amifostine/cisplatin complex in vitro and its ability in repairing bone defect and eliminating tumor in vivo]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May;41(3):471-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug delivery of CPC/amifostine/cisplatin complex in vitro and its ability in repairing bone defect and eliminating tumor in vivo].
  • METHODS: Drug concentration in the CPC/ amifostine/cisplatin complex was determined.
  • Rabbits with bone defect and rats with osteosarcoma were implanted with CPC and CPC/amifostine/cisplatin complex.
  • RESULTS: Similar bone growth was observed in the femurs of rabbits implanted with CPC/amifostine/cisplatin complex and those implanted with CPC.
  • CPC/amifostine/cisplatin complex delivered amifostine and cisplatin consistently and eliminated osteosarcoma cells implanted in the rats.
  • CONCLUSION: CPC/amifostine/cisplatin complex repairs bone defect caused by tumors as a filling material.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629324.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Cements; 0 / Calcium Phosphates; 97Z1WI3NDX / calcium phosphate; M487QF2F4V / Amifostine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Xu S, Li D, Wang C, Wang Z, Lu B: Cell proliferation in CPC scaffold with a central channel. Biomed Mater Eng; 2007;17(1):1-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation in CPC scaffold with a central channel.
  • Calcium phosphate cement (CPC) scaffold design should improve nutrient and cell transfer to the scaffold centre.
  • In this study, CPC scaffolds with a single central channel were fabricated indirectly using a stereolithography rapid prototyping (RP) technology.
  • Preliminary demonstration from the data that the minimum channel diameter required for cell migration into and adhesion on CPC scaffold was approximately 72 microm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264382.001).
  • [ISSN] 0959-2989
  • [Journal-full-title] Bio-medical materials and engineering
  • [ISO-abbreviation] Biomed Mater Eng
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Calcium Phosphates; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


17. Dutta SJ, Liu J, Stemmler AJ, Mitra B: Conservative and nonconservative mutations of the transmembrane CPC motif in ZntA: effect on metal selectivity and activity. Biochemistry; 2007 Mar 27;46(12):3692-703
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative and nonconservative mutations of the transmembrane CPC motif in ZntA: effect on metal selectivity and activity.
  • P1B-type ATPases can be divided into subgroups based on substrate cation selectivity.
  • Pro393 is invariant in all P-type ATPases.
  • Histidine and serine substitutions at Cys392 and Cys394 resulted in loss of binding of Pb2+ at the transmembrane site, indicating that both cysteines of the CPC motif are required for binding Pb2+ with high affinity in ZntA homologues.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326661.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM-61689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations, Divalent; 0 / Ligands; 0 / Metals, Heavy; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / Zn(II)-translocating P-type ATPase
  •  go-up   go-down


18. Zhong Z, Chen Q, Chen Y, Liu C: [Repair of bone defect due to tumor resection with self-setting CPC in children]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct;22(10):1196-9
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Repair of bone defect due to tumor resection with self-setting CPC in children].
  • OBJECTIVE: To summarize the effect of self-setting CPC on the repair of bone defect after tumor resection in children.
  • METHODS: From December 1998 to December 2006, 32 patients with benign bone tumor were treated, and the bone defect was repaired by CPC.
  • CPC spongiosa granules of 3-23 g were filled in 26 cases, including 3 children with pathologic fracture and internal fixation with plate, and injectable CPC of 5-20 mL was filled in 6 bone cyst cases.
  • There was no pain or pruritus at the incisions.
  • The X-ray films showed that the implanted CPC began to fuse with the host bone 4-9 months (7 month on average) after operation.
  • And CPC spongiosa granules were absolutely absorbed within 8-36 months of operation.
  • However, injectable CPC could be found 4 years after operation.
  • CONCLUSION: CPC in repairing bone defect after benign bone tumor in children is a safe, economical, convenient and non-toxic method.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979877.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes; 0 / Hydroxyapatites
  •  go-up   go-down


19. Versteeg PA, Rosema NA, Hoenderdos NL, Slot DE, Van der Weijden GA: The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model - a cross-over study. Int J Dent Hyg; 2010 Nov;8(4):269-75
Hazardous Substances Data Bank. Hexetidine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model - a cross-over study.
  • OBJECTIVE: To test the plaque inhibitory effect of an experimental 0.07% cetylpyridinium chloride (CPC) mouthrinse in a 3-day plaque accumulation model in a cross-over design.
  • Over three sessions, the mean plaque scores were 2.17 for the control product, 1.14 for the CPC group and 1.12 for the 0.1% Hexetidine product (positive control).
  • Results of the questionnaire show that, compared with hexetidine, the taste of the CPC was appreciated better, and less oral sensations were observed following rinsing.
  • CONCLUSION: The CPC mouthrinse proved to be effective in inhibiting 'de novo' plaque formation to an extent similar to that of a 0.1% hexetidine product.
  • Compared with hexetidine, the taste of the CPC was appreciated better and less oral sensations were observed following rinsing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard.
  • (PMID = 20961382.001).
  • [ISSN] 1601-5037
  • [Journal-full-title] International journal of dental hygiene
  • [ISO-abbreviation] Int J Dent Hyg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Mouthwashes; 852A84Y8LS / Hexetidine; CUB7JI0JV3 / Cetylpyridinium
  •  go-up   go-down


20. Kost GJ, Tran NK: Point-of-Care Testing and Cardiac Biomarkers: The Standard of Care and Vision for Chest Pain Centers. Cardiol Clin; 2005 Nov;23(4):467-90, vi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Point-of-Care Testing and Cardiac Biomarkers: The Standard of Care and Vision for Chest Pain Centers.
  • POC technologies have become ubiquitous in the United States, and, therefore,so has the potential for speed, convenience, and satisfaction, strong advantages for physicians, nurses, and patients in chest pain centers.
  • Chest pain centers, which now total over 150 accredited in the United States, incorporate similar types of protocol-driven performance enhancements.
  • This optimization allows chest pain centers to improve patient evaluation, treatment, survival, and discharge.
  • This article focuses on cardiac biomarker POCT for chest pain centers and emergency medicine.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278118.001).
  • [ISSN] 0733-8651
  • [Journal-full-title] Cardiology clinics
  • [ISO-abbreviation] Cardiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 147
  •  go-up   go-down


21. Zhong R, Fei Q, Zhang J, Chen T, Liu C, Long Z, Yu R, Huang H: [Bone inductive effects of rhBMP-2 loaded porous CPC implants on spine fusion in rabbits]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Feb;23(2):231-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone inductive effects of rhBMP-2 loaded porous CPC implants on spine fusion in rabbits].
  • OBJECTIVE: To investigate the effect of rhBMP-2 combined with porous CPC on spine fusion in rabbits.
  • METHODS: rhBMP-2 (1 mg) was loaded with 1 g CPC and 6.0 cm x 2.0 cm x 0.5 cm absorbable gelatin sponge (AGS), respectively, and thereafter frozen to prepare the biomaterial of rhBMP-2/CPC and rhBMP-2/AGS.
  • With the exposure and removal of L5,6 transverse process's posterior bone cortex in all the rabbits, the corresponding cancellous bones were exposed and the posterior bilateral intertransverse bone grafting of L5,6 were performed on the three groups, then the rhBMP-2/CPC, rhBMP-2/AGS and CPC was implanted into the rabbits of group A, B and C, respectively.
  • CONCLUSION: As a carrier of rhBMP-2, the CPC is capable of promoting spine bone fusion in rabbits and is a new type of artificial bone repair material.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275111.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Proteins; 0 / Bone Substitutes; 0 / Drug Carriers; 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta; 0 / recombinant human bone morphogenetic protein-2
  •  go-up   go-down


22. Tang H, Xu Z, Liu C, Qin X, Wu B, Wu L: [Preparation of CPC for tissue engineering artificial rib and a study on proliferation and adhesion of BMSCs on CPC]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct;22(10):1238-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preparation of CPC for tissue engineering artificial rib and a study on proliferation and adhesion of BMSCs on CPC].
  • OBJECTIVE: To access the possibility of CPC as a suitable scaffold for tissue engineering artificial rib by morphologic observation, adhesion experiments and cellar proliferation experiments.
  • METHODS: The 5 mm x 5 mm x 5 mm CPCs were prepared and the structure and components of CPC were compared with those of the normal human bone by micro-CT and scanning electron microscope.
  • There was 150 microL suspension which was inoculated on the CPC, and then cells were recollected and counted 4, 12 and 24 hours after inoculation.
  • MTT was used to examine the growth condition of BMSCs on the surface of CPC.
  • The scanning electron microscope was used to observe the CPC scaffold 7 days after inoculation, and comparison was made with CPC and the normal human bone.
  • RESULTS: The adhesion rate of CPC was 28.00% +/- 0.98%, 46.70% +/- 1.14% and 48.50% +/- 1.18%, respectively 4, 12 and 24 hours after compound culture.
  • The proliferation rate of CPC was 1.103 +/- 0.214, 1.557 +/- 0.322, 1.920 +/- 0.178, 2.564 +/- 0.226, 2.951 +/- 0.415 and 3.831 +/- 0.328, respectively 1, 2, 3, 4, 5 and 6 days after compound culture, with an obvious rising trend.
  • The rate of the cell adhesion to CPC was less than 50%.
  • CONCLUSION: The structure and components of CPC are similar to those of the normal human bone, and BMSCs grow well on the surface of it, so it is a suitable scaffold for tissue engineering artificial rib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979886.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Substitutes; 0 / Hydroxyapatites
  •  go-up   go-down


23. Chen WC, Ju CP, Chern Lin JH: Variation in structure and properties of a non-dispersive TTCP/DCPA-derived CPC immersed in Hanks' solution. J Oral Rehabil; 2007 Jul;34(7):541-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in structure and properties of a non-dispersive TTCP/DCPA-derived CPC immersed in Hanks' solution.
  • The present work is to characterize a non-dispersive, fast-setting and high-strength tetra calcium phosphate (TTCP)/dicalcium phosphate anhydrous (DCPA)-based calcium phosphate cement (nd-CPC) recently developed in the authors' laboratory.
  • Comparison between this CPC and a conventional TTCP/DCPA-based CPC (c-CPC) is made.
  • The results show that, during setting c-CPC reaches its pH plateau after 10 min, while nd-CPC approaches plateau after 20 min.
  • The nd-CPC has a higher apatite formation rate and denser structure than c-CPC under similar conditions, especially at early stage.
  • The nd-CPC also demonstrates higher strength both during setting and after immersion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559622.001).
  • [ISSN] 0305-182X
  • [Journal-full-title] Journal of oral rehabilitation
  • [ISO-abbreviation] J Oral Rehabil
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Dental Cements; 0 / Hanks Balanced Salt Solution; 0 / Isotonic Solutions; 0 / Organ Preservation Solutions; 0 / tetracalcium phosphate; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


24. Vokácová Z, Budĕsínský M, Rosenberg I, Schneider B, Sponer J, Sychrovský V: Structure and dynamics of the ApA, ApC, CpA, and CpC RNA dinucleoside monophosphates resolved with NMR scalar spin-spin couplings. J Phys Chem B; 2009 Jan 29;113(4):1182-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure and dynamics of the ApA, ApC, CpA, and CpC RNA dinucleoside monophosphates resolved with NMR scalar spin-spin couplings.
  • The dynamical characteristics of the two nucleosides are not equivalent even for the ApA and CpC homologues.
  • The geometries of the nucleobases classified in this work as stacked were significantly more populated for the DMP molecules with adenosine at the 3' end (ApA and CpA DMPs) than the ApC or CpC RNA molecules with C at the 3' end.

  • Hazardous Substances Data Bank. Adenosine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128019.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dinucleoside Phosphates; 63231-63-0 / RNA; 8J337D1HZY / Cytosine; JAC85A2161 / Adenine; K72T3FS567 / Adenosine
  •  go-up   go-down


25. Judkins AR, Burger PC, Hamilton RL, Kleinschmidt-DeMasters B, Perry A, Pomeroy SL, Rosenblum MK, Yachnis AT, Zhou H, Rorke LB, Biegel JA: INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol; 2005 May;64(5):391-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma.
  • Central nervous system atypical teratoid/rhabdoid tumor (AT/RT) and choroid plexus carcinoma (CPC) are rare, highly malignant tumors that predominantly arise in infants and young children.
  • Overlapping clinical, histologic, ultrastructural, or immunophenotypic features may obscure the diagnosis in some cases.
  • Mutations of INI1 in some CPCs have been reported.
  • The purpose of the present study was to determine if immunohistochemical staining with an INI1 antibody would provide a sensitive means of distinguishing between CPC and AT/RT.
  • We examined 28 tumors with a submitted diagnosis of CPC.
  • Twenty-one CPCs showed retained expression of INI1 and seven tumors showed loss of INI1 expression.
  • In three of the seven cases, monosomy 22 was the only cytogenetic abnormality, suggestive of AT/RT.
  • Immunostaining for INI1 protein is retained in the majority of CPC and is lost in AT/RT.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Choroid Plexus Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic / physiology. Teratoma / metabolism

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892296.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46274; United States / NCI NIH HHS / CA / CA98543
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Mucin-1; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


26. Postovsky S, Vlodavsky E, Eran A, Guilburd J, Ben Arush MW: Secondary glioblastoma multiforme after treatment for primary choroid plexus carcinoma in childhood. J Pediatr Hematol Oncol; 2007 Apr;29(4):248-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary glioblastoma multiforme after treatment for primary choroid plexus carcinoma in childhood.
  • A 15-year-old boy was diagnosed with choroid plexus carcinoma (CPC) of the right lateral ventricle.
  • The patient remained in complete clinical and radiologic remission over the next 5 years when a secondary malignant tumor, glioblastoma multiforme, a rare complication of the treatment of CPC, was diagnosed.
  • This case reflects the necessity of thorough follow-up in long-term survivors of CPC.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Etoposide / administration & dosage. Fatal Outcome. Humans. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414567.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Kumar B, Feller JF, Castro M, Lu J: Conductive bio-Polymer nano-Composites (CPC): chitosan-carbon nanotube transducers assembled via spray layer-by-layer for volatile organic compound sensing. Talanta; 2010 May 15;81(3):908-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conductive bio-Polymer nano-Composites (CPC): chitosan-carbon nanotube transducers assembled via spray layer-by-layer for volatile organic compound sensing.
  • The chemo-electrical properties of chitosan-carbon nanotubes (Chit-CNT) Conductive bio-Polymer nano-Composites (CPC) transducers processed by spray layer-by-layer (LbL) technique have been investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298872.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nanotubes, Carbon; 0 / Polymers; 0 / Solvents; 0 / Volatile Organic Compounds; 9012-76-4 / Chitosan
  •  go-up   go-down


28. Colina-Márquez J, Machuca-Martínez F, Li Puma G: Photocatalytic mineralization of commercial herbicides in a pilot-scale solar CPC reactor: photoreactor modeling and reaction kinetics constants independent of radiation field. Environ Sci Technol; 2009 Dec 1;43(23):8953-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photocatalytic mineralization of commercial herbicides in a pilot-scale solar CPC reactor: photoreactor modeling and reaction kinetics constants independent of radiation field.
  • In this study, the above approach was extended to model the photocatalytic mineralization of a commercial herbicides mixture (2,4-D, diuron, and ametryne used in Colombian sugar cane crops) in a solar, pilot-scale, compound parabolic collector (CPC) photoreactor using a slurry suspension of TiO(2).
  • The ray-tracing technique was used jointly with the SFM to determine the direction of both the direct and diffuse solar photon fluxes and the spatial profile of the local volumetric rate of photon absorption (LVRPA) in the CPC reactor.
  • The results showed that the overall model fitted the experimental data of herbicides mineralization in the solar CPC reactor satisfactorily for both cloudy and sunny days.
  • Using the above approach kinetic parameters independent of the radiation field in the reactor can be estimated directly from the results of experiments carried out in a solar CPC reactor.

  • MedlinePlus Health Information. consumer health - Minerals.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943672.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Herbicides; 0 / Minerals; 7440-44-0 / Carbon
  •  go-up   go-down


29. Turan RG, Brehm M, Köstering M, Bartsch T, Zeus T, Picard F, Steiner S, Fleissner T, Ilousis D, Augusta K, Kister M, Rüttger C, Schannwell CM, Strauer BE: [Effects of exercise training on mobilization of BM-CPCs and migratory capacity as well as LVEF after AMI]. Med Klin (Munich); 2006 Mar 22;101 Suppl 1:198-201
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of exercise training on mobilization of BM-CPCs and migratory capacity as well as LVEF after AMI].
  • BACKGROUND AND PURPOSE: Bone marrow-derived circulating progenitor cells (BM-CPCs) are mobilized in adult peripheral blood (PB) during the acute myocardial infarction (AMI) period and contribute to the regeneration of infarcted myocardium.
  • In this study, the influence of physical training on the mobilization and the migratory activity of the BM-CPCs as well as on the left ventricular function (LVEF) after AMI was examined.
  • The migratory activity of BM-CPCs was analyzed by migration assay.
  • B-type natriuretic peptide (BNP) in PB and the functional investigations spiroergometry (VO2 and PaO2) and stress echocardiography (LVEF) were determined in both groups.
  • RESULTS: A significant increase in both concentrations, CD34/45+ and CD133/45+, as well as in migratory capacity of BM-CPCs was found after 3 weeks of exercise training, which was significantly decreased 3 months after completion of exercise training.
  • CONCLUSION: This study demonstrates that exercise training for 3 weeks after AMI leads to a significant mobilization as well as increase of functional activation of BM-CPCs in humans.

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802555.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 114471-18-0 / Natriuretic Peptide, Brain; S88TT14065 / Oxygen
  •  go-up   go-down


30. Lucas MS, Mosteo R, Maldonado MI, Malato S, Peres JA: Solar photochemical treatment of winery wastewater in a CPC reactor. J Agric Food Chem; 2009 Dec 9;57(23):11242-8
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solar photochemical treatment of winery wastewater in a CPC reactor.
  • Degradation of simulated winery wastewater was studied in a pilot-scale compound parabolic collector (CPC) solar reactor.

  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899762.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Industrial Waste; 15FIX9V2JP / titanium dioxide; D1JT611TNE / Titanium
  •  go-up   go-down


31. Bordbar AK, Taheri-Kafrani A: Binding and fluorescence study on interaction of human serum albumin (HSA) with cetylpyridinium chloride (CPC). Colloids Surf B Biointerfaces; 2007 Mar 15;55(1):84-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Binding and fluorescence study on interaction of human serum albumin (HSA) with cetylpyridinium chloride (CPC).
  • In the present study, results are presented for the binding of cetylpyridinium chloride (CPC) with HSA at various pH and 25 degrees C, as monitored using ion selective membrane electrodes and fluorescence spectroscopy of intrinsic tryptophan.
  • CPC quenched the fluorescence arising from Trp group incorporated to HSA.
  • The Stern-Volmer behavior observed at low molar ratio of [CPC]/[HSA] (about 6), that represents the occurrence of conformational changes after this molar ratio.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17208422.001).
  • [ISSN] 0927-7765
  • [Journal-full-title] Colloids and surfaces. B, Biointerfaces
  • [ISO-abbreviation] Colloids Surf B Biointerfaces
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Serum Albumin; CUB7JI0JV3 / Cetylpyridinium
  •  go-up   go-down


32. Mazloom A, Wolff JE, Paulino AC: The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):79-84
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for choroid plexus carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma.
  • PURPOSE: To perform a comprehensive literature review and analysis of cases dealing with choroid plexus carcinoma (CPC) to determine the optimal radiotherapy (RT) treatment field.
  • The median age at diagnosis was 2.7 years (range, 1 month-53 years).
  • Of 54 patients with data regarding type of surgery, 21 (38.9%) had complete resection.
  • CONCLUSION: Patients with CPC who received CSI had better PFS compared with those receiving less than CSI.
  • This study supports the use of CSI in the multimodality management of patients with CPC.
  • [MeSH-major] Carcinoma / radiotherapy. Choroid Plexus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20004534.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


33. Fuso A, Ferraguti G, Grandoni F, Ruggeri R, Scarpa S, Strom R, Lucarelli M: Early demethylation of non-CpG, CpC-rich, elements in the myogenin 5'-flanking region: a priming effect on the spreading of active demethylation. Cell Cycle; 2010 Oct 1;9(19):3965-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early demethylation of non-CpG, CpC-rich, elements in the myogenin 5'-flanking region: a priming effect on the spreading of active demethylation.
  • Demethylation spread from initially highly methylated short CpC-rich elements to a virtually unmethylated status.
  • These short elements have a high CpC content and density, share some motifs and largely coincide with putative recognition sequences of some differentiation-related transcription factors.
  • The short CpC-rich elements are new structural features of the methylation machinery, whose functions may include priming the complete demethylation of a transcriptionally crucial DNA region.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Feb 20;22(7):1070-2 [12592393.001]
  • [Cites] Curr Issues Mol Biol. 2002 Oct;4(4):111-28 [12432963.001]
  • [Cites] J Gene Med. 2004 Apr;6(4):395-404 [15079814.001]
  • [Cites] Nat Rev Genet. 2004 Jun;5(6):446-55 [15153997.001]
  • [Cites] Biometals. 2004 Jun;17(3):317-23 [15222484.001]
  • [Cites] Nature. 1977 Dec 22-29;270(5639):725-7 [563524.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Jun 15;145(2):888-94 [3593377.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1277-89 [8391506.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7612-24 [8246978.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):579-83 [10050851.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28787-93 [10497251.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):8-16 [15681469.001]
  • [Cites] Gene. 2005 Mar 28;348:123-34 [15777718.001]
  • [Cites] DNA Res. 2004 Dec 31;11(6):409-15 [15871463.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):20171-5 [15778220.001]
  • [Cites] Nucleic Acids Res. 2005;33(18):5868-77 [16224102.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):299-307 [16125822.001]
  • [Cites] Cell Mol Biol Lett. 2005;10(4):631-47 [16341272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1412-7 [16432200.001]
  • [Cites] Trends Biochem Sci. 2006 Feb;31(2):89-97 [16403636.001]
  • [Cites] Anal Biochem. 2006 Mar 1;350(1):24-31 [16445884.001]
  • [Cites] Biochem Cell Biol. 2006 Aug;84(4):463-76 [16936820.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):66-71 [17214963.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):671-5 [17268471.001]
  • [Cites] Cell. 2007 Feb 23;128(4):707-19 [17320508.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):368-79 [17559830.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):248-51 [17713477.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):148-9 [17851501.001]
  • [Cites] Curr Top Dev Biol. 2008;80:337-60 [17950379.001]
  • [Cites] Epigenetics. 2007 Jan-Mar;2(1):54-65 [17965591.001]
  • [Cites] Nature. 2008 Mar 6;452(7183):45-50 [18322525.001]
  • [Cites] Nature. 2008 Mar 6;452(7183):112-5 [18322535.001]
  • [Cites] Gene. 2008 Jun 15;416(1-2):22-9 [18442886.001]
  • [Cites] Nat Rev Genet. 2008 Jun;9(6):465-76 [18463664.001]
  • [Cites] J Mol Biol. 2008 Jul 4;380(2):265-77 [18513743.001]
  • [Cites] Cell. 2008 Jun 27;133(7):1145-8 [18585349.001]
  • [Cites] Gene. 2008 Sep 1;420(2):99-106 [18602768.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):40-8 [18407786.001]
  • [Cites] Nature. 2008 Aug 7;454(7205):766-70 [18600261.001]
  • [Cites] Nucleic Acids Res. 2008 Dec;36(22):e150 [18984622.001]
  • [Cites] Mol Cell Biol. 2010 Aug;30(15):3805-15 [20498275.001]
  • [Cites] Neurobiol Aging. 2011 Feb;32(2):187-99 [19329227.001]
  • [Cites] Biochem J. 2004 Mar 15;378(Pt 3):763-8 [14636159.001]
  • [Cites] Genomics. 2000 Mar 1;64(2):132-43 [10729220.001]
  • [Cites] Curr Biol. 2000 Apr 20;10(8):475-8 [10801417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5135-9 [10779566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5237-42 [10805783.001]
  • [Cites] DNA Cell Biol. 2000 Sep;19(9):521-6 [11034545.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7500-6 [11096088.001]
  • [Cites] J Mol Biol. 2001 Jun 22;309(5):1201-8 [11399089.001]
  • [Cites] Nucleic Acids Res. 2001 Sep 1;29(17):3506-12 [11522819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10404-9 [11504918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10034-6 [11526227.001]
  • [Cites] FEBS Lett. 2001 Nov 23;508(3):337-40 [11728447.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):245-53 [11776477.001]
  • [Cites] Dev Biol. 2001 Dec 15;240(2):585-98 [11784085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Nat Rev Genet. 2002 Sep;3(9):662-73 [12209141.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:747-83 [12142270.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7572-80 [12370304.001]
  • [CommentIn] Cell Cycle. 2010 Oct 1;9(19):3846-7 [20948285.001]
  • (PMID = 20935518.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myogenin
  • [Other-IDs] NLM/ PMC3047754
  •  go-up   go-down


34. Shi Y, Zhang L, Yuan J, Xiao H, Yang X, Niu L: Zinc binding site in PICK1 is dominantly located at the CPC motif of its PDZ domain. J Neurochem; 2008 Aug;106(3):1027-34
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc binding site in PICK1 is dominantly located at the CPC motif of its PDZ domain.
  • PICK1 (protein interacting with Ckinase 1) containing a PDZ domain, a BAR domain, and two short acidic regions is as an adaptor protein that plays an important role in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor trafficking, cell morphology and migration, as well as in some diseases such as cancer, schizophrenia and pain.
  • The mutation of the CPC (Cys-Pro-Cys) motif in the PDZ domain of PICK1 abolishes the ability of Zn2+-binding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429931.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / Prkcabp protein, rat; J41CSQ7QDS / Zinc
  •  go-up   go-down


35. Chakraborty T, Ghosh S, Moulik SP: Micellization and related behavior of binary and ternary surfactant mixtures in aqueous medium: cetyl pyridinium chloride (CPC), cetyl trimethyl ammonium bromide (CTAB), and polyoxyethylene (10) cetyl ether (Brij-56) derived system. J Phys Chem B; 2005 Aug 11;109(31):14813-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micellization and related behavior of binary and ternary surfactant mixtures in aqueous medium: cetyl pyridinium chloride (CPC), cetyl trimethyl ammonium bromide (CTAB), and polyoxyethylene (10) cetyl ether (Brij-56) derived system.
  • Mixed micelles formed with cetyl pyridinium chloride (CPC), cetyl trimethylammonium bromide (CTAB), and polyoxyethylene (10) cetyl ether (Brij-56) mixed in different combinations in aqueous medium have been studied in detail by tensiometric, conductometric, calorimetric, spectrophotometric, and fluorimetric techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16852875.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Saunée NA, Williams SR, Bryant DA, Schluchter WM: Biogenesis of phycobiliproteins: II. CpcS-I and CpcU comprise the heterodimeric bilin lyase that attaches phycocyanobilin to CYS-82 OF beta-phycocyanin and CYS-81 of allophycocyanin subunits in Synechococcus sp. PCC 7002. J Biol Chem; 2008 Mar 21;283(12):7513-22
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biogenesis of phycobiliproteins: II. CpcS-I and CpcU comprise the heterodimeric bilin lyase that attaches phycocyanobilin to CYS-82 OF beta-phycocyanin and CYS-81 of allophycocyanin subunits in Synechococcus sp. PCC 7002.
  • PCC 7002 genome encodes three genes, denoted cpcS-I, cpcU, cpcV, with sequence similarity to cpeS.
  • CpcS-I copurified with His(6)-tagged (HT) CpcU as a heterodimer, CpcSU.
  • When no enzyme or CpcS-I or CpcU was added alone, the products had absorbance maxima between 645 and 647 nm and were not fluorescent.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1992 Aug 15;267(23):16138-45 [1644801.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):7503-12 [18199754.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7017-21 [1495995.001]
  • [Cites] J Photochem Photobiol B. 1992 Aug 14;15(1-2):75-89 [1460543.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8686-94 [8132596.001]
  • [Cites] Biochim Biophys Acta. 1994 Jul 29;1186(3):153-62 [8043589.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12877-84 [7759546.001]
  • [Cites] J Mol Biol. 1995 Jun 2;249(2):424-40 [7783202.001]
  • [Cites] J Bacteriol. 1997 Feb;179(4):998-1006 [9023176.001]
  • [Cites] J Bacteriol. 1999 Jan;181(2):610-7 [9882677.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1363-8 [9990029.001]
  • [Cites] FEBS Lett. 2000 Mar 3;469(1):9-13 [10708746.001]
  • [Cites] Plant Cell. 2001 Feb;13(2):425-36 [11226195.001]
  • [Cites] Plant Cell. 2001 Apr;13(4):965-78 [11283349.001]
  • [Cites] Mol Microbiol. 2002 Jun;44(6):1517-31 [12067341.001]
  • [Cites] Arch Microbiol. 2002 Oct;178(4):256-66 [12209258.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9219-26 [12514179.001]
  • [Cites] Biochemistry. 2003 Dec 2;42(47):13800-11 [14636046.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 9;1657(2-3):131-45 [15238270.001]
  • [Cites] J Biol Chem. 1973 Jan 25;248(2):659-62 [4630849.001]
  • [Cites] Biochem J. 1979 Sep 1;181(3):577-83 [117797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(24):7946-50 [6096868.001]
  • [Cites] Methods Enzymol. 1988;167:291-303 [3148835.001]
  • [Cites] Biochim Biophys Acta. 1989 Oct 26;977(1):40-51 [2508754.001]
  • [Cites] Arch Microbiol. 1990;153(6):541-9 [2114862.001]
  • [Cites] Arch Microbiol. 1990;153(6):550-60 [2164365.001]
  • [Cites] Biochim Biophys Acta. 1990 Aug 9;1019(1):29-41 [2118804.001]
  • [Cites] J Biol Chem. 1991 Apr 15;266(11):7239-47 [1901865.001]
  • [Cites] Biochemistry. 1992 Mar 31;31(12):3092-102 [1554697.001]
  • [Cites] J Mol Biol. 1986 Apr 20;188(4):651-76 [3090271.001]
  • [Cites] J Mol Biol. 1987 Aug 5;196(3):677-95 [3119857.001]
  • [Cites] J Biol Chem. 1988 Dec 5;263(34):18343-9 [3142876.001]
  • [Cites] J Biol Chem. 1989 Jan 5;264(1):1-4 [2491842.001]
  • [Cites] Biochim Biophys Acta. 2005 Jan 7;1706(1-2):81-7 [15620367.001]
  • [Cites] Biochemistry. 2005 Jun 7;44(22):8126-37 [15924432.001]
  • [Cites] J Biol Chem. 2006 Mar 31;281(13):8573-81 [16452471.001]
  • [Cites] Biochemistry. 2006 Jun 13;45(23):7092-9 [16752899.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):17768-78 [16644722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14300-5 [17726096.001]
  • [Cites] J Biol Chem. 1992 Aug 15;267(23):16146-54 [1644802.001]
  • (PMID = 18199753.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM-31625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Phycobilins; 0 / allophycocyanin; 11016-15-2 / Phycocyanin; 20298-86-6 / phycocyanobilin; EC 4.- / Lyases; EC 4.4.- / phycocyanin alpha-subunit phycocyanobilin lyase
  • [Other-IDs] NLM/ PMC2276331
  •  go-up   go-down


37. Ross MA, Amsterdam E, Peacock WF, Graff L, Fesmire F, Garvey JL, Kelly S, Holmes K, Karunaratne HB, Toth M, Dadkhah S, McCord J: Chest pain center accreditation is associated with better performance of centers for Medicare and Medicaid services core measures for acute myocardial infarction. Am J Cardiol; 2008 Jul 15;102(2):120-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chest pain center accreditation is associated with better performance of centers for Medicare and Medicaid services core measures for acute myocardial infarction.
  • The aim of this study was determine whether hospitals accredited by the Society of Chest Pain Centers hospitals (accredited chest pain centers [ACPCs]) are associated with better performance regarding Centers for Medicare and Medicaid Services core measures for acute myocardial infarction (AMI) than nonaccredited hospitals.
  • The study was a retrospective, observational cohort study of hospitals reporting Centers for Medicare and Medicaid Services core measures for AMI from January 1, 2005, to December 31, 2005, on the basis of the presence or absence of Society of Chest Pain Centers accreditation.
  • Data were obtained from the Web sites of the Centers for Medicare and Medicaid Services (Hospital Compare), Society of Chest Pain Centers listings, and the American Hospital Directory.
  • In conclusion, ACPCs were associated with better compliance with Centers for Medicare and Medicaid Services core measures and saw a greater proportion of patients with AMIs.
  • [MeSH-major] Accreditation. Cardiac Care Facilities / standards. Chest Pain. Medicaid. Medicare. Myocardial Infarction. Quality of Health Care
  • [MeSH-minor] Benchmarking. Centers for Medicare and Medicaid Services (U.S.). Humans. Logistic Models. Models, Statistical. Retrospective Studies. United States

  • MedlinePlus Health Information. consumer health - Chest Pain.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Medicaid.
  • MedlinePlus Health Information. consumer health - Medicare.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602506.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Bullitt E, Wolthusen PA, Brubaker L, Lin W, Zeng D, Van Dyke T: Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice. AJNR Am J Neuroradiol; 2006 Mar;27(3):612-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy-associated vessel tortuosity: a computer-assisted, MR angiographic study of choroid plexus carcinoma in genetically engineered mice.
  • This report describes the MR imaging characteristics of a genetically engineered mouse model of choroid plexus carcinoma (CPC) during tumor growth and progression to malignancy.
  • We assess the ability of vessel tortuosity measurements, as calculated from high-resolution MR angiographic (MRA) images, to detect emerging CPC cancers.
  • METHODS: MR images of 9 healthy mice and of 20 CPC mice with precancerous choroid dysplasia or with cancer over a wide range of sizes were analyzed.
  • RESULTS: Choroid dysplasia was correctly judged nonmalignant.
  • CONCLUSION: To the best of our knowledge, this report provides the first description of in vivo, MR imaging characteristics of genetically engineered CPC mice during the progression from dysplasia to cancer.
  • Vessel tortuosity measurements offer promise of correctly defining even tiny tumors as malignant.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Aug 26;78(4):703-11 [8069917.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8218-23 [16166297.001]
  • [Cites] Acad Radiol. 2005 Oct;12(10):1232-40 [16179200.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):6017-30 [11486039.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2186-9 [11691952.001]
  • [Cites] Cell. 2002 Jan 25;108(2):135-44 [11832204.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):783-9 [12185064.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] Neuroradiology. 2003 Apr;45(4):205-11 [12687302.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):421-37 [14973386.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • (PMID = 16552004.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53783; NLM/ PMC2504702
  •  go-up   go-down


39. Cater MA, La Fontaine S, Mercer JF: Copper binding to the N-terminal metal-binding sites or the CPC motif is not essential for copper-induced trafficking of the human Wilson protein (ATP7B). Biochem J; 2007 Jan 1;401(1):143-53
Hazardous Substances Data Bank. COPPER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Copper binding to the N-terminal metal-binding sites or the CPC motif is not essential for copper-induced trafficking of the human Wilson protein (ATP7B).
  • The Wilson protein (ATP7B) is a copper-translocating P-type ATPase that mediates the excretion of excess copper from hepatocytes into bile.
  • In addition, mutation of the six N-terminal metal-binding sites and/or the trans-membrane CPC (Cys-Pro-Cys) motif did not suppress the constitutive vesicular localization of the ATP7B phosphatase domain mutant.

  • MedlinePlus Health Information. consumer health - Wilson Disease.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Aug 12;9(13):1927-35 [10942420.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):493-506 [16472602.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28620-7 [11373292.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36289-94 [11470780.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46736-42 [12228238.001]
  • [Cites] Biometals. 2003 Mar;16(1):175-84 [12572677.001]
  • [Cites] Ann N Y Acad Sci. 2003 Apr;986:204-11 [12763797.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32212-8 [12794172.001]
  • [Cites] Genomics. 2004 Mar;83(3):473-81 [14962673.001]
  • [Cites] Placenta. 2004 Jul;25(6):512-7 [15135234.001]
  • [Cites] Biochem J. 2004 Jun 15;380(Pt 3):805-13 [14998371.001]
  • [Cites] J Inorg Biochem. 2004 Sep;98(9):1483-94 [15337600.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1463-71 [15269005.001]
  • [Cites] Gene. 1987;52(2-3):225-33 [3038686.001]
  • [Cites] EMBO J. 1988 Jun;7(6):1793-8 [2901955.001]
  • [Cites] Pediatr Res. 1990 Aug;28(2):137-41 [1975662.001]
  • [Cites] J Biol Chem. 1990 Dec 25;265(36):22223-7 [2148317.001]
  • [Cites] Gene. 1991 Apr;100:195-9 [2055470.001]
  • [Cites] FEBS Lett. 1992 Jul 27;307(1):20-5 [1639189.001]
  • [Cites] Biotechniques. 1992 Jul;13(1):18-20 [1503765.001]
  • [Cites] J Histochem Cytochem. 1999 Dec;47(12):1553-62 [10567439.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1380-5 [10579979.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):7-13 [8490659.001]
  • [Cites] Nat Genet. 1993 Dec;5(4):327-37 [8298639.001]
  • [Cites] Nat Genet. 1993 Dec;5(4):344-50 [8298641.001]
  • [Cites] FEBS Lett. 1994 Sep 5;351(2):186-90 [8082762.001]
  • [Cites] Hum Mol Genet. 1994 Sep;3(9):1647-56 [7833924.001]
  • [Cites] Yeast. 1995 Mar;11(3):283-92 [7785328.001]
  • [Cites] Biochim Biophys Acta. 1996 May 6;1286(1):1-51 [8634322.001]
  • [Cites] Trends Biochem Sci. 1996 Jul;21(7):237-41 [8755241.001]
  • [Cites] Hum Mol Genet. 1996 Oct;5(10):1619-24 [8894697.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6084-95 [8947031.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18939-44 [9228074.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21461-6 [9261163.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1815-20 [9430732.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10854-9 [9724794.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1663-74 [9837819.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 1):G639-46 [10070040.001]
  • [Cites] Adv Exp Med Biol. 1999;448:83-95 [10079817.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):11170-7 [10196202.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):22008-12 [10419525.001]
  • [Cites] Hum Mutat. 1999;14(1):88 [10447265.001]
  • [Cites] Curr Opin Cell Biol. 1999 Aug;11(4):517-22 [10449329.001]
  • [Cites] Hum Mol Genet. 1999 Oct;8(11):2107-15 [10484781.001]
  • [Cites] Hum Mol Genet. 2001 Feb 15;10(4):361-70 [11157799.001]
  • (PMID = 16939419.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cation Transport Proteins; 0 / DNA Primers; 0 / Oligopeptides; 2ZD004190S / Threonine; 3KX376GY7L / Glutamic Acid; 789U1901C5 / Copper; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.4 / Wilson disease protein; K848JZ4886 / Cysteine; TE7660XO1C / Glycine
  • [Other-IDs] NLM/ PMC1698686
  •  go-up   go-down


40. Itoh T, Ishikawa H, Hayashi Y: Asymmetric aldol reaction of acetaldehyde and isatin derivatives for the total syntheses of ent-convolutamydine E and CPC-1 and a half fragment of madindoline A and B. Org Lett; 2009 Sep 3;11(17):3854-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymmetric aldol reaction of acetaldehyde and isatin derivatives for the total syntheses of ent-convolutamydine E and CPC-1 and a half fragment of madindoline A and B.
  • Short syntheses of ent-convolutamydine E and CPC-1 and a half fragment of madindoline A and B have been accomplished.

  • Hazardous Substances Data Bank. ACETALDOL .
  • Hazardous Substances Data Bank. ACETALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19655732.001).
  • [ISSN] 1523-7052
  • [Journal-full-title] Organic letters
  • [ISO-abbreviation] Org. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Alkaloids; 0 / Bicyclo Compounds, Heterocyclic; 0 / Indoles; 0 / madindoline A; 107-89-1 / 3-hydroxybutanal; 82X95S7M06 / Isatin; GO1N1ZPR3B / Acetaldehyde
  •  go-up   go-down


41. Schaeffer MW, Brennan TD, Hughes JA, Gibler WB, Gerson MC: Resting radionuclide myocardial perfusion imaging in a chest pain center including an overnight delayed image acquisition protocol. J Nucl Med Technol; 2007 Dec;35(4):242-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resting radionuclide myocardial perfusion imaging in a chest pain center including an overnight delayed image acquisition protocol.
  • Emergency department (ED) patients with chest pain (CP) and a nondiagnostic electrocardiogram (ECG) present difficult management decisions.
  • The purpose of this study was to investigate the utility of resting radionuclide SPECT myocardial perfusion imaging (SPECT MPI)-including an overnight delayed image acquisition protocol-in identifying patients presenting to the ED with CP at risk for cardiac events.
  • METHODS: Patients presenting to the ED with CP and a nondiagnostic ECG were prospectively enrolled and underwent chest pain center evaluation.
  • Among the 3 patients with a normal perfusion scan who suffered cardiac events, all had tracer injection several hours after resolution of CP.
  • [MeSH-major] Chest Pain. Gated Blood-Pool Imaging. Pain Clinics. Rest / physiology. Time. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Acute Disease / epidemiology. Adult. Aged. Aged, 80 and over. Electrocardiography. Female. Heart Diseases / complications. Heart Diseases / epidemiology. Humans. Male. Middle Aged. Organophosphorus Compounds / pharmacokinetics. Organotechnetium Compounds / pharmacokinetics. Perfusion. Radioisotopes / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics. Risk Assessment. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Chest Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006599.001).
  • [ISSN] 0091-4916
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


42. Park JY, Koo IS, Sohn CH, Kim JS, Cho GH, Park HS: Development of a cause analysis system for a CPCS trip by using the rule-base deduction method. ISA Trans; 2009 Jul;48(3):362-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a cause analysis system for a CPCS trip by using the rule-base deduction method.
  • A Core Protection Calculator System (CPCS) was developed to initiate a Reactor Trip under the circumstance of certain transients by a Combustion Engineering Company.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249777.001).
  • [ISSN] 1879-2022
  • [Journal-full-title] ISA transactions
  • [ISO-abbreviation] ISA Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Chandra A, Glickman SW, Ou FS, Peacock WF, McCord JK, Cairns CB, Peterson ED, Ohman EM, Gibler WB, Roe MT: An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. Ann Emerg Med; 2009 Jul;54(1):17-25
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence.
  • STUDY OBJECTIVE: Since 2003, the Society of Chest Pain Centers (SCPC) has provided hospital accreditation for acute coronary syndrome care processes.
  • RESULTS: Of 33,238 patients treated at 21 accredited hospitals and 323 nonaccredited hospitals, those at SCPC-accredited centers (n=3,059) were more likely to receive aspirin (98.1% versus 95.8%; odds ratio [OR] 1.73; 95% confidence interval [CI] 1.06 to 2.83) and beta-blockers (93.4% versus 90.6%; OR 1.68; 95% CI 1.04 to 2.70) within 24 hours than patients at non-SCPC-accredited centers (n=30,179).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282062.001).
  • [ISSN] 1097-6760
  • [Journal-full-title] Annals of emergency medicine
  • [ISO-abbreviation] Ann Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Fibrinolytic Agents; 0 / Platelet Aggregation Inhibitors; 0 / Platelet Glycoprotein GPIIb-IIIa Complex; 9005-49-6 / Heparin; R16CO5Y76E / Aspirin
  •  go-up   go-down


44. Moloney C, Griffin D, Jones PW, Bryan GJ, McLean K, Bradshaw JE, Milbourne D: Development of diagnostic markers for use in breeding potatoes resistant to Globodera pallida pathotype Pa2/3 using germplasm derived from Solanum tuberosum ssp. andigena CPC 2802. Theor Appl Genet; 2010 Feb;120(3):679-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of diagnostic markers for use in breeding potatoes resistant to Globodera pallida pathotype Pa2/3 using germplasm derived from Solanum tuberosum ssp. andigena CPC 2802.
  • Quantitative resistance to Globodera pallida pathotype Pa2/3, originally derived from Solanum tuberosum ssp. andigena Commonwealth Potato Collection (CPC) accession 2802, is present in several potato cultivars and advanced breeding lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1995 Nov 11;23(21):4407-14 [7501463.001]
  • [Cites] Theor Appl Genet. 1994 Aug;88(6-7):764-9 [24186175.001]
  • [Cites] Theor Appl Genet. 2003 May;106(8):1517-23 [12750795.001]
  • [Cites] J Hered. 2007 Nov-Dec;98(7):727-9 [17965198.001]
  • [Cites] Genetics. 2006 Jun;173(2):1075-87 [16582432.001]
  • [Cites] Mol Plant Microbe Interact. 2005 Nov;18(11):1186-94 [16353553.001]
  • [Cites] Theor Appl Genet. 2002 Jul;105(1):68-77 [12582563.001]
  • [Cites] Genome. 2007 Apr;50(4):412-21 [17546099.001]
  • [Cites] Annu Rev Phytopathol. 2001;39:79-102 [11701860.001]
  • [Cites] Mol Plant Microbe Interact. 2005 Jul;18(7):722-9 [16042018.001]
  • (PMID = 19882336.001).
  • [ISSN] 1432-2242
  • [Journal-full-title] TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
  • [ISO-abbreviation] Theor. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


45. Mizuguchi K, Kawasugi K, Asano H, Kimura S: [Reversed CPC: forty years old male with leg phlegmon]. Rinsho Byori; 2006 Feb;54(2):184-7
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reversed CPC: forty years old male with leg phlegmon].

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548240.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Moncayo-Lasso A, Pulgarin C, Benítez N: Degradation of DBPs' precursors in river water before and after slow sand filtration by photo-Fenton process at pH 5 in a solar CPC reactor. Water Res; 2008 Sep;42(15):4125-32
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Degradation of DBPs' precursors in river water before and after slow sand filtration by photo-Fenton process at pH 5 in a solar CPC reactor.
  • In this study the degradation of NOM model compounds (dihydroxy-benzene) as well as the removal of NOM from river water via photo-Fenton process in a CPC solar photo-reactor is presented.

  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Water Res. 2010 Mar;44(5):1680
  • (PMID = 18718626.001).
  • [ISSN] 0043-1354
  • [Journal-full-title] Water research
  • [ISO-abbreviation] Water Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Disinfectants; 0 / Fenton's reagent; 0 / Ferric Compounds; 0 / Water Pollutants, Chemical; 7631-86-9 / Silicon Dioxide; BBX060AN9V / Hydrogen Peroxide; E1UOL152H7 / Iron
  •  go-up   go-down


47. Russell-Swetek A, West AN, Mintern JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP: Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet; 2008 Sep;45(9):603-6
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.
  • Paediatric choroid plexus carcinomas (CPC) and adrenocortical carcinomas (ACC) are exceedingly rare tumours, each occurring at an annual rate of 0.3 cases per million children or less.
  • Although both tumour types are associated with Li-Fraumeni syndrome (LFS), the penetrance of germline TP53 mutations in CPC remains to be established.
  • We report here a young boy without a family history of cancer who presented with CPC and subsequently ACC.
  • Genetic testing revealed a novel de novo germline TP53 mutation (E285V).
  • These results further strengthen the association between germline TP53 mutations and childhood CPC, even when occurring in the absence of familial tumour susceptibility.

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854256 for PMID:18762572 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1998 Nov;57(11):1061-9 [9825943.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):265-73 [15747338.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5056-62 [16707427.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):370-3 [17671971.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6C):5563-5 [10697617.001]
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):995-1006 [10486318.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):15-30 [11602342.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):70-2 [11800650.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Genes Dev. 1992 Jul;6(7):1143-52 [1628822.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • (PMID = 18762572.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA63230; United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA23944; United States / NCI NIH HHS / CA / R01 CA063230
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS404658; NLM/ PMC3487594
  •  go-up   go-down


48. Wrede B, Liu P, Wolff JE: Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol; 2007 Dec;85(3):345-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors.
  • BACKGROUND: Choroid plexus carcinomas (CPC) are rare brain tumors with a dismal prognosis.
  • METHODS: We created a database of all cases of choroid plexus tumors (CPT) reported in the literature up to the year 2004 to determine prognostic factors and different therapeutic modalities.
  • RESULTS: Of 857 documented cases of CPT (median patient age at diagnosis, 3 years), 347 were CPC, 15 atypical choroid plexus papilloma (APP), and 495 choroid plexus papilloma (CPP).
  • Within the subgroup of patients with CPC, both surgery and irradiation were linked to a better prognosis (P < .005).
  • The 104 CPC patients who received chemotherapy had a statistically better survival than those without chemotherapy (P = .0004).
  • The benefit of chemotherapy was also significant when the analysis was restricted to the subgroup of patients with less than completely resected CPC (2-year overall survival (OS) 54.8 +/- 7% (standard deviation (SD) vs. 24.4 +/- 7%, P < .0001) and when this subgroup was further divided into smaller subgroups.
  • CONCLUSION: Patients with less than completely resected CPC should receive chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576522.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


49. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID, Kulkarni AV, Bartels U, Greenberg M, Bouffet E: Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr; 2010 Jun;5(6):615-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma.
  • OBJECT: Choroid plexus carcinomas (CPCs) are rare pediatric tumors with a generally poor prognosis.
  • In this paper, the authors' goal was to assess the role of second-look surgery and neoadjuvant ifosfamide, carboplatin, etoposide (ICE) chemotherapy in the management of CPC and to study neurocognitive outcome.
  • METHODS: The authors performed an institutional retrospective review of patients in whom CPC was diagnosed between 1985 and 2006 at the Hospital for Sick Children in Toronto.
  • The median age at diagnosis was 18.6 months (range 1.1-65.3 months).
  • Four patients had evidence of metastatic disease at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / surgery. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515336.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


50. Dickens DS, Dothage JA, Heideman RL, Ballard ET, Jubinsky PT: Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome. J Pediatr Hematol Oncol; 2005 Jan;27(1):46-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome.
  • Choroid plexus carcinoma (CPC) is an uncommon central nervous system tumor requiring complete surgical excision for favorable outcome.
  • The authors report the successful treatment of a 2-year-old patient with widely disseminated CPC and Li-Fraumeni syndrome.
  • Additional studies are necessary to determine whether this treatment plan can be beneficial to other patients with CPC and whether the patient's p53 mutation had an effect on outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy. Li-Fraumeni Syndrome / drug therapy. Neoplasm Metastasis / drug therapy

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654279.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


51. Taverna E: Chest pain centers: surviving the accreditation process. Nurs Manage; 2007 Apr;38(4):42, 44-50
MedlinePlus Health Information. consumer health - Heart Attack.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chest pain centers: surviving the accreditation process.
  • [MeSH-major] Accreditation. Cardiac Care Facilities / organization & administration. Chest Pain / diagnosis. Myocardial Infarction. Pain Clinics / organization & administration

  • MedlinePlus Health Information. consumer health - Chest Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415224.001).
  • [ISSN] 0744-6314
  • [Journal-full-title] Nursing management
  • [ISO-abbreviation] Nurs Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Martínez-León MI, Weil-Lara B, Herrero-Hernández A: [Papilloma and carcinoma of the choroid plexus in pediatric patients]. Radiologia; 2007 Jul-Aug;49(4):279-86
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papilloma and carcinoma of the choroid plexus in pediatric patients].
  • [Transliterated title] Papiloma y carcinoma de plexos coroideos en la edad pediátrica.
  • Papillomas of the choroid plexus are rare tumors of neuroectodermal origin; they represent less than 5% of all central nervous system (CNS) tumors in pediatric patients.
  • Choroid plexus carcinomas are even rarer.
  • We reviewed the incidence of these neoplasms at our reference hospital and found six tumors of the choroid plexus (five papillomas and one carcinoma) in five patients.
  • All patients underwent surgery; total resection was achieved in the five papillomas, whereas the carcinoma was partially resected and the patient is currently undergoing chemotherapy.
  • The three patients with a single papilloma are disease free at follow-up (range 7 months to 11 years).
  • The patient with two papillomas shows good recovery at follow-up, whereas the patient with carcinoma of the choroid plexus has a poor prognosis.
  • [MeSH-major] Carcinoma. Choroid Plexus Neoplasms. Papilloma
  • [MeSH-minor] Female. Humans. Infant. Infant, Newborn. Male. Prenatal Diagnosis

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594892.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


53. Singh A, Vermani S, Shruti S: Choroid plexus carcinoma: report of two cases. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):405-7
Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus carcinoma: report of two cases.
  • Choroid plexus carcinomas (CPCs) are rare malignant counterparts of choroid plexus papilloma which occur in infants and children with a predilection for the posterior fossa and have a poor prognosis.
  • We report two cases of CPC diagnosed in a 5-year-old boy and a 12-year-old boy and discuss the clinicopathologic features.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / pathology. Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / pathology
  • [MeSH-minor] Animals. Child. Child, Preschool. Choroid Plexus / pathology. Histocytochemistry. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679976.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


54. Klopfleisch R, Beier D, Teifke JP: Choroid plexus carcinoma in a goat. J Comp Pathol; 2006 Jul;135(1):42-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus carcinoma in a goat.
  • Post-mortem examination of the brain revealed a large, unilateral, well-demarcated, intraventricular neoplasm which was diagnosed as a choroid plexus carcinoma.
  • This is the first report of a choroid plexus carcinoma in a goat.
  • [MeSH-major] Carcinoma / pathology. Choroid Plexus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820166.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


55. Fabi A, Salesi N, Di Cocco B, Vidiri A, Visca P, Pace A, Carapella C, De Paula U, Mirri A, Cognetti F: Choroid plexus carcinoma in the adult: is there a role for chemotherapy? J Exp Clin Cancer Res; 2005 Sep;24(3):493-6
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus carcinoma in the adult: is there a role for chemotherapy?
  • Choroid plexus carcinoma is a rare primary brain neoplasm arising from epithelial differentiated tissue, originating from the choroids plexus of the ventricles and, in 90% of the cases, in the lateral and fourth ventricles.
  • The treatment of choroid plexus carcinoma is based on scarce evidence in literature.
  • We report a rare case of an adult woman affected by a choroid plexus tumour and a discussion on the therapeutic management of this uncommon adult malignancy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Papilloma / drug therapy

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270538.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; BG3F62OND5 / Carboplatin; K2I13DR72L / Gadolinium DTPA; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Le Péchoux C, Besse B, Ferreira I, Bretel JJ, Bruna A, Mazeron R, Amarouch A, Roberti E: [Small cell lung cancer (CPC). Management of patients presenting with limited stage small cell carcinoma of the lung]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S188-16S197
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell lung cancer (CPC). Management of patients presenting with limited stage small cell carcinoma of the lung].
  • [Transliterated title] Les cancers à petites cellules. Modalités actuelles de la prise en charge des patients présentant un carcinome bronchique à petites cellules localisé.
  • Small cell carcinomas represent less than 20% of all lung cancer.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268357.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 66
  •  go-up   go-down


57. Jorgensen M, Bate J, Gatscher S, Chisholm JC: Invasive pneumococcal disease following treatment for choroid plexus carcinoma. Support Care Cancer; 2010 May;18(5):647-50
MedlinePlus Health Information. consumer health - Pneumococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive pneumococcal disease following treatment for choroid plexus carcinoma.
  • INTRODUCTION: A 13-month-old child was treated for choroid plexus carcinoma with partial embolisation, complete surgical excision and chemotherapy.
  • [MeSH-major] Choroid Plexus Neoplasms / drug therapy. Pneumococcal Infections / diagnosis. Streptococcus pneumoniae / isolation & purification

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 2002 Jun;86(6):403-6 [12023167.001]
  • [Cites] Br J Haematol. 2009 Dec;147(5):700-5 [19764991.001]
  • [Cites] Clin Infect Dis. 2009 May 15;48(10):1392-401 [19368505.001]
  • [Cites] Acta Paediatr Suppl. 2000 Dec;89(435):11-6 [11194790.001]
  • [Cites] J Infect Dis. 2002 Apr 1;185(7):927-36 [11920317.001]
  • [Cites] Br J Haematol. 2002 May;117(2):444-50 [11972532.001]
  • [Cites] Br J Haematol. 2007 Jun;137(5):457-60 [17488489.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2322-6 [17090650.001]
  • [Cites] Pediatr Infect Dis J. 2002 Feb;21(2):141-7 [11840082.001]
  • [Cites] J Immunol Methods. 2005 Jan;296(1-2):135-47 [15680158.001]
  • [Cites] Clin Infect Dis. 2007 Mar 1;44(5):635-42 [17278052.001]
  • [Cites] Pediatrics. 2008 Jul;122(1):e26-32 [18595971.001]
  • [Cites] Arch Dis Child. 2003 Aug;88(8):712-4 [12876171.001]
  • [Cites] J Clin Immunol. 1995 May;15(3):137-44 [7559916.001]
  • [Cites] Pediatr Infect Dis J. 2000 Mar;19(3):187-95 [10749457.001]
  • (PMID = 20076974.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Krutilkova V, Trkova M, Fleitz J, Gregor V, Novotna K, Krepelova A, Sumerauer D, Kodet R, Siruckova S, Plevova P, Bendova S, Hedvicakova P, Foreman NK, Sedlacek Z: Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer; 2005 Jul;41(11):1597-603
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.
  • We present five families of paediatric patients suffering from choroid plexus carcinoma in which we found germline TP53 mutations.
  • In the remaining two families no family history of cancer was identified and/or the parents of the patient were shown not to carry the mutation.
  • Our results give further support to the notion that the occurrence of this rare paediatric tumour, especially in combination with a positive family history of cancer, but possibly also without any family history, may be an indicator of a germline TP53 mutation.
  • The identification of this genetic defect has important consequences for cancer prevention and treatment in affected families.
  • [MeSH-major] Choroid Plexus Neoplasms / genetics. Genes, p53 / genetics. Germ-Line Mutation / genetics

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925506.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


59. Karami KJ, Poulik J, Rabah R, Krass J, Sood S: Simultaneous choroid plexus carcinoma and pilocytic astrocytoma in a pediatric patient. J Neurosurg Pediatr; 2010 Jan;5(1):104-12
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous choroid plexus carcinoma and pilocytic astrocytoma in a pediatric patient.
  • The authors report the case of a 4-year-old boy with simultaneous choroid plexus carcinoma and pilocytic astrocytoma with features of oligodendroglioma.
  • Magnetic resonance imaging studies revealed diffuse heterogeneously enhancing left intraventricular and posterior fossa tumors initially believed most consistent with multicentric choroid plexus carcinomas.
  • Upon gross inspection intraoperatively as well as postoperative histological analysis, 2 distinct simultaneous tumors were identified: choroid plexus carcinoma and pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / surgery. Fourth Ventricle / surgery. Lateral Ventricles / surgery. Magnetic Resonance Imaging. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Neuronavigation. Thalamus / surgery. Tomography, X-Ray Computed


60. Wrede B, Liu P, Ater J, Wolff JE: Second surgery and the prognosis of choroid plexus carcinoma--results of a meta-analysis of individual cases. Anticancer Res; 2005 Nov-Dec;25(6C):4429-33
Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second surgery and the prognosis of choroid plexus carcinoma--results of a meta-analysis of individual cases.
  • Tumors of the choroid plexus (CPT) are rare.
  • While choroid plexus papillomas (CPP) are regarded as benign, choroid plexus carcinomas (CPC) have a dismal prognosis, and there is limited information available regarding the best treatment.
  • Maximal possible surgery is generally believed to be the major prognostic factor, but data to answer the question, of whether second surgery improves the prognosis of CPC have been missing.
  • Three hundred and forty-seven patients had CPC, 15 atypical choroid plexus papillomas (APP) and 495 CPP.
  • In CPP, complete resection was more frequently achieved (80.4%) than in APP (61.5%) or CPC (39.6%).
  • Among the subgroup of incompletely resected CPC, 22.6% of the patients had second surgery.
  • The prognosis of these patients appeared better when compared to incompletely resected CPC without second surgery (2-year overall survival 69% versus 30%).
  • This study suggests, if complete resection is not possible in the first surgery of a choroid plexus carcinoma, a second resection should be considered.
  • [MeSH-major] Choroid Plexus Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334121.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Greece
  • [Number-of-references] 22
  •  go-up   go-down


61. Stevens EA, Stanton CA, Nichols K, Ellis TL: Rare intraparenchymal choroid plexus carcinoma resembling atypical teratoid/rhabdoid tumor diagnosed by immunostaining for INI1 protein. J Neurosurg Pediatr; 2009 Oct;4(4):368-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare intraparenchymal choroid plexus carcinoma resembling atypical teratoid/rhabdoid tumor diagnosed by immunostaining for INI1 protein.
  • The authors present the case of a rare extraventricular, intraparenchymal choroid plexus carcinoma (CPC).
  • The initial pathological diagnosis was atypical teratoid/rhabdoid tumor (AT/RT); however, immunostaining for INI1 protein (using the BAF47/SNF5 antibody) showed retention of nuclear staining in the tumor cells, resulting in a change in the diagnosis to CPC.
  • There was no evidence of recurrence at the last follow-up 2.5 years after treatment, which supports the diagnosis of CPC over AT/RT.
  • This case emphasizes the importance of immunostaining for INI1 protein for distinguishing CPC from AT/RT in cases with atypical or indeterminate features.
  • [MeSH-major] Biomarkers, Tumor / analysis. Choroid Plexus Neoplasms / pathology. Chromosomal Proteins, Non-Histone / analysis. DNA-Binding Proteins / analysis. Rhabdoid Tumor / pathology. Teratoma / pathology. Transcription Factors / analysis
  • [MeSH-minor] Cell Nucleus / pathology. Child. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795969.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


62. Chai J, Lu X, Godfrey V, Fletcher C, Roberts CW, Van Dyke T, Weissman BE: Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation. Cancer Res; 2007 Apr 1;67(7):3002-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant rhabdoid tumors (MRT) are rare aggressive cancers that occur in young children.
  • The diagnosis of choroid plexus carcinomas (CPC) in addition to MRTs in families with a single mutant SNF5 allele prompted us to assess the role of SNF5 loss in CPC in genetically engineered mice.
  • With high frequency, TgT(121) mice develop CPCs that are initiated by inactivation of retinoblastoma protein (pRb) and related proteins p107 and p130.
  • However, CPC penetrance and latency were not significantly affected by Snf5 heterozygosity, consistent with recent evidence that CPCs in SNF5 families were, in many cases, misdiagnosed MRTs.
  • Surprisingly, although the CPC phenotype was unaffected, TgT(121);Snf5(+/-) mice developed MRTs with increased penetrance and decreased latency compared with TgT(121);Snf5(+/+) littermates.
  • The predominant appearance of TgT(121);Snf5(+/-) MRTs in the spinal cord led to the discovery that these tumors likely arose from a subset of spinal cord neural progenitor cells expressing T(121) rather than from transdifferentiation of CPC.
  • Significantly, the target cell type(s) for MRT is unknown.
  • [MeSH-major] Choroid Plexus Neoplasms / genetics. Chromosomal Proteins, Non-Histone / genetics. Retinoblastoma Protein / genetics. Rhabdoid Tumor / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409406.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA046283; United States / NCI NIH HHS / CA / R01CA091048; United States / NCI NIH HHS / CA / R01CA113794
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA, Neoplasm; 0 / Retinoblastoma Protein; 0 / Smarcb1 protein, mouse
  •  go-up   go-down


63. Westworth DR, Dickinson PJ, Vernau W, Johnson EG, Bollen AW, Kass PH, Sturges BK, Vernau KM, Lecouteur RA, Higgins RJ: Choroid plexus tumors in 56 dogs (1985-2007). J Vet Intern Med; 2008 Sep-Oct;22(5):1157-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors in 56 dogs (1985-2007).
  • BACKGROUND: Choroid plexus tumors (CPTs) comprise approximately 10% of all primary brain tumors in dogs.
  • The clinical utility of magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, or both in the presumptive diagnosis of CPTs has not been determined.
  • RESULTS: Thirty-six of 56 dogs had a choroid plexus carcinoma (CPC) and 20 had a choroid plexus papilloma (CPP).
  • Median CSF protein concentration in CPCs (108 mg/dL, range 27-380 mg/dL) was significantly higher than in CPPs (34 mg/dL, range 32-80 mg/dL) (P= .002).
  • Only dogs with CPCs had a CSF protein concentration >80 mg/dL.
  • Cytological evidence of malignancy in CSF was seen in 7 of 15 CPCs.
  • Only CPCs had evidence of intraventricular or subarachnoid metastases on MRI.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: MRI, CSF analysis or both can help to differentiate between CPPs and CPCs, and may provide valuable prognostic and pretreatment information.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691364.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D: TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol; 2010 Apr 20;28(12):1995-2001
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors.
  • PURPOSE Choroid plexus carcinomas are pediatric tumors with poor survival rates and a strong, but poorly understood, association with Li-Fraumeni syndrome (LFS).
  • PATIENTS AND METHODS We established a multi-institutional tissue and clinical database, which enabled the analysis of specific alterations of the TP53 tumor suppressor and its modifiers in choroid plexus tumors (CPTs).
  • All individuals with germline TP53 mutations fulfilled LFS criteria, whereas all patients not meeting these criteria harbored wild-type TP53 (P < .001).
  • TP53 mutations were found in 50% of choroid plexus carcinomas (CPCs).
  • Additionally, two sequence variants known to confer TP53 dysfunction, TP53 codon72 and MDM2 SNP309, coexisted in the majority of TP53 wild-type CPCs (92%) and not in TP53 mutated CPC (P = .04), which suggests a complementary mechanism of TP53 dysfunction in the absence of a TP53 mutation.
  • High-resolution single nucleotide polymorphism (SNP) array analysis revealed extremely high total structural variation (TSV) in TP53-mutated CPC tumor genomes compared with TP53 wild-type tumors and choroid plexus papillomas (CPPs; P = .006 and .004, respectively).
  • Five-year survival rates for patients with TP53-immunopositive and -immunonegative CPCs were 0% and 82 (+/- 9%), respectively (P < .001).
  • Furthermore, 14 of 16 patients with TP53 wild-type CPCs are alive without having received radiation therapy.
  • CONCLUSION Patients with CPC who have low tumor TSV and absence of TP53 dysfunction have a favorable prognosis and can be successfully treated without radiation therapy.
  • [MeSH-major] Carcinoma / genetics. Choroid Plexus Neoplasms / genetics. Germ-Line Mutation. Papilloma, Choroid Plexus / genetics. Polymorphism, Single Nucleotide. Tumor Suppressor Protein p53 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308654.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP82727; Canada / Canadian Institutes of Health Research / / MOP86558
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


65. Vader G, Medema RH, Lens SM: The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol; 2006 Jun 19;173(6):833-7
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During mitosis, the chromosomal passenger complex (CPC) orchestrates highly different processes, such as chromosome alignment, histone modification, and cytokinesis.
  • Proper and timely localization of this complex is the key to precise control over the enzymatic core of the CPC, the Aurora-B kinase.
  • We discuss the molecular mechanisms by which the CPC members direct the dynamic localization of the complex throughout cell division.
  • Also, we summarize posttranslational modifications that occur on the CPC and discuss their roles in regulating localization and function of this mitotic complex.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13208-13 [10557299.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2547-58 [16571674.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):173-82 [10949038.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):183-9 [10949039.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1162-71 [11050384.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):122-7 [11139336.001]
  • [Cites] J Cell Biol. 2001 Nov 26;155(5):763-74 [11724818.001]
  • [Cites] Mol Biol Cell. 2002 Apr;13(4):1099-108 [11950924.001]
  • [Cites] Mol Biol Cell. 2002 Sep;13(9):3064-77 [12221116.001]
  • [Cites] J Cell Biol. 2003 Mar 31;160(7):993-9 [12654903.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):281-94 [12707311.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):229-36 [12707312.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):267-80 [12719470.001]
  • [Cites] Mol Biol Cell. 2003 Aug;14(8):3325-41 [12925766.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54 [14625535.001]
  • [Cites] Science. 2003 Dec 19;302(5653):2120-4 [14605209.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5655-60 [14610074.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):179-91 [15249581.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):167-72 [15263015.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4033-42 [15280424.001]
  • [Cites] Chromosoma. 1991 Mar;100(3):139-46 [2040201.001]
  • [Cites] J Cell Biol. 1993 Oct;123(2):373-85 [8408220.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] J Cell Biol. 1998 Dec 28;143(7):1763-74 [9864353.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):927-36 [15573114.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):379-91 [15866179.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1499-504 [16322459.001]
  • [Cites] Nature. 2005 Dec 22;438(7071):1176-80 [16222244.001]
  • [Cites] Nature. 2005 Dec 22;438(7071):1116-22 [16222246.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):85-92 [16239925.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17(4):1897-909 [16436504.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5391-6 [16565220.001]
  • [Cites] Nat Struct Biol. 2000 Jul;7(7):602-8 [10876248.001]
  • (PMID = 16769825.001).
  • [ISSN] 0021-9525
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Chromosomal Proteins, Non-Histone; 0 / Microtubule-Associated Proteins; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 33
  • [Other-IDs] NLM/ PMC2063908
  •  go-up   go-down


66. Menon G, Nair SN, Baldawa SS, Rao RB, Krishnakumar KP, Gopalakrishnan CV: Choroid plexus tumors: an institutional series of 25 patients. Neurol India; 2010 May-Jun;58(3):429-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors: an institutional series of 25 patients.
  • PURPOSE: Choroid plexus tumors (CPT) are rare neoplasms that pose considerable treatment challenges.
  • RESULTS: The study group included 12 (48%) cases of choroid plexus papilloma (CPP), 09 (36%) cases of choroid plexus carcinoma (CPC) and 4 cases of atypical CPP.
  • A complete surgical excision was achieved in 11 cases of CPP and 8 cases of CPC.
  • All patients with CPP had a good outcome at the end of a mean follow-up of 5.4 years, whereas the median survival for patients with CPCs who underwent a subtotal resection with adjuvant therapy was 36 months.
  • CONCLUSION: CPTs include a spectra ranging from CPP to CPC.
  • CPCs and atypical CPCs carry a poor prognosis, and adjuvant therapy improves survival marginally after total excision.
  • Spinal drop metastases are common for CPC and screening of the spine for possible metastasis should be part of the routine preoperative and postoperative investigation protocol.
  • [MeSH-major] Choroid Plexus Neoplasms / therapy. Combined Modality Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644273.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


67. Vader G, Lens SM: Chromosome segregation: taking the passenger seat. Curr Biol; 2010 Oct 26;20(20):R879-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chromosomal passenger complex (CPC) is a major regulator of mitotic and meiotic chromosome segregation.
  • Three recent papers now elucidate the mechanisms that determine the localization of the CPC to the inner centromere.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20971428.001).
  • [ISSN] 1879-0445
  • [Journal-full-title] Current biology : CB
  • [ISO-abbreviation] Curr. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Microtubule-Associated Proteins; 0 / Multiprotein Complexes; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


68. Agarwalla PK, Dunn IF, Turner CD, Ligon KL, Schneider KA, Smith ER: A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature. Pediatr Neurosurg; 2008;44(6):501-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Choroid plexus carcinoma (CPC) has been associated with TP53 germline mutations and Li-Fraumeni syndrome (LFS).
  • We describe our finding of a novel germline mutation in the TP53 gene in a family with multiple malignancies and in association with a child presenting with CPC.
  • METHOD: An 8-month-old male presented with seizure-like activity; imaging disclosed a 1.5-cm left ventricular mass confirmed to be CPC intra- and postoperatively.
  • CONCLUSION: Physicians treating patients with CPC should be attuned to reviewing family history for risk factors suggestive of genetic cancer syndromes such as LFS.
  • [MeSH-minor] Amino Acid Substitution / genetics. Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / genetics. Female. Humans. Infant. Li-Fraumeni Syndrome / diagnosis. Li-Fraumeni Syndrome / genetics. Male. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Pedigree. Sarcoma / diagnosis. Sarcoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19127094.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 63
  •  go-up   go-down


69. Zakrzewska M, Wojcik I, Zakrzewski K, Polis L, Grajkowska W, Roszkowski M, Augelli BJ, Liberski PP, Rieske P: Mutational analysis of hSNF5/INI1 and TP53 genes in choroid plexus carcinomas. Cancer Genet Cytogenet; 2005 Jan 15;156(2):179-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of hSNF5/INI1 and TP53 genes in choroid plexus carcinomas.
  • We report here the mutational analysis of hSNF5/INI1 and TP53 genes performed on 11 specimens of choroid plexus carcinomas (CPC) in which a large number of abnormalities has been detected by molecular biology techniques.
  • Our analysis confirms the presence of the hSNF5/INI1 mutations and proves involvement of TP53 mutations in sporadic cases of CPC.
  • [MeSH-major] Choroid Plexus Neoplasms / genetics. DNA Mutational Analysis. DNA-Binding Proteins / genetics. Genes, p53 / genetics. Loss of Heterozygosity. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642401.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


70. Donovan DJ, Prauner RD: Shunt-related abdominal metastases in a child with choroid plexus carcinoma: case report. Neurosurgery; 2005 Feb;56(2):E412; discussion E412
Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shunt-related abdominal metastases in a child with choroid plexus carcinoma: case report.
  • Choroid plexus tumors (CPTs) are located within the cerebrospinal fluid-containing spaces of the brain and frequently disseminate throughout the craniospinal subarachnoid space, yet VPS-related metastasis of a CPT to the abdomen has not been reported previously.
  • CLINICAL PRESENTATION: We present the case of a 3-year-old boy with choroid plexus carcinoma of the lateral ventricle and preoperative intraventricular dissemination of the tumor.
  • When the child presented with abdominal ascites, the distal VPS catheter was externalized and drained cerebrospinal fluid at a rate of more than 750 ml/d.
  • [MeSH-major] Abdominal Neoplasms / etiology. Abdominal Neoplasms / secondary. Carcinoma / etiology. Carcinoma / secondary. Choroid Plexus Neoplasms / pathology. Ventriculoperitoneal Shunt / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670391.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Moncayo-Lasso A, Sanabria J, Pulgarin C, Benítez N: Simultaneous E. coli inactivation and NOM degradation in river water via photo-Fenton process at natural pH in solar CPC reactor. A new way for enhancing solar disinfection of natural water. Chemosphere; 2009 Sep;77(2):296-300
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous E. coli inactivation and NOM degradation in river water via photo-Fenton process at natural pH in solar CPC reactor. A new way for enhancing solar disinfection of natural water.

  • MedlinePlus Health Information. consumer health - Germs and Hygiene.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716153.001).
  • [ISSN] 1879-1298
  • [Journal-full-title] Chemosphere
  • [ISO-abbreviation] Chemosphere
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Organic Chemicals; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


72. Carmena M: Cytokinesis: the final stop for the chromosomal passengers. Biochem Soc Trans; 2008 Jun;36(Pt 3):367-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CPC (chromosomal passenger complex) performs essential roles in the regulation and co-ordination of chromosomal and cytoskeletal events during mitosis and meiosis.
  • The first functional analyses showed evidence of a role of the CPC in the regulation of cytokinesis.
  • In this review, I summarize what we have learned since then about the role of the CPC in the late stages of mitosis and cytokinesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481960.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 9013-26-7 / Actomyosin
  • [Number-of-references] 39
  •  go-up   go-down


73. Tena-Suck ML, Salinas-Lara C, Rembao-Bojórquez D, Castillejos M: Clinicopathologic and immunohistochemical study of choroid plexus tumors: single-institution experience in Mexican population. J Neurooncol; 2010 Jul;98(3):357-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical study of choroid plexus tumors: single-institution experience in Mexican population.
  • In recent years, few studies have specifically focused on only histological features in choroid plexus tumors.
  • We retrospectively reviewed the clinicopathologic and histological features in 37 patients with choroid plexus tumors and correlated these with glial fibrillary acidic protein (GFAP) expression and proliferation cell nuclear antigen (PCNA), p53, p21, and Rb labeling indexes, with special attention to tumor recurrence/regrowth.
  • The study included 24 choroid plexus papillomas (CPPs), 4 atypical choroid plexus papillomas (ACPPs), and 9 choroid plexus carcinomas (CPCs).
  • Most of the choroid plexus tumors were located in the IV ventricle.
  • Recurrence was observed in 21 (52%) cases, 14 of which were CPP and 7 of which were CPC (P = 0.032).
  • The PCNA labeling index was 52.04 + or - 13.92 in CPPs, 76.50 + or - 17 in ACPPs, and 95.22 + or - 21.34 in CPCs (P = 0.009), and 67.43 + or - 28 in recurrent tumors.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma / pathology. Choroid Plexus Neoplasms / metabolism. Choroid Plexus Neoplasms / pathology. Papilloma, Choroid Plexus / metabolism. Papilloma, Choroid Plexus / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082118.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glial Fibrillary Acidic Protein; 0 / Proliferating Cell Nuclear Antigen; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


74. Kurata T, Ishida T, Kawabata-Awai C, Noguchi M, Hattori S, Sano R, Nagasaka R, Tominaga R, Koshino-Kimura Y, Kato T, Sato S, Tabata S, Okada K, Wada T: Cell-to-cell movement of the CAPRICE protein in Arabidopsis root epidermal cell differentiation. Development; 2005 Dec;132(24):5387-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CAPRICE (CPC), a small, R3-type Myb-like protein, is a positive regulator of root hair development in Arabidopsis.
  • Cell-to-cell movement of CPC is important for the differentiation of epidermal cells into trichoblasts (root hair cells).
  • CPC is transported from atrichoblasts (hairless cells), where it is expressed, to trichoblasts, and generally accumulates in their nuclei.
  • Using truncated versions of CPC fused to GFP, we identified a signal domain that is necessary and sufficient for CPC cell-to-cell movement.
  • Amino acid substitution experiments indicated that W76 and M78 in the Myb domain are critical for targeted transport, and that W76 is crucial for the nuclear accumulation of CPC:GFP.
  • To evaluate the tissue-specificity of CPC movement, CPC:GFP was expressed in the stele using the SHR promoter and in trichoblasts using the EGL3 promoter.
  • CPC:GFP was able to move from trichoblasts to atrichoblasts but could not exit from the stele, suggesting the involvement of tissue-specific regulatory factors in the intercellular movement of CPC.
  • Analyses with a secretion inhibitor, Brefeldin A, and with an rhd3 mutant defective in the secretion process in root epidermis suggested that intercellular CPC movement is mediated through plasmodesmata.
  • Furthermore, the fusion of CPC to tandem-GFPs defined the capability of CPC to increase the size exclusion limit of plasmodesmata.


75. Guo F, Li B: [Recent developments of researches on calcium phosphate cements]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb;26(1):202-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The research of calcium phosphate cement (CPC) has been developing for more than 20 years.
  • In this review, we present a brief introduction to recent advances in researches on apatite CPC, brushite CPC, composite CPC materials; on factors affecting CPC capability and application; and on new application of CPC.
  • The view that emphasizes the significance of studies on CPC with quicker degradation and osteoblast activity is put forward, particularly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19334587.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bone Cements; 0 / Bone Substitutes; 0 / Calcium Phosphates; 97Z1WI3NDX / calcium phosphate
  • [Number-of-references] 26
  •  go-up   go-down


76. Maxeiner H, Krehbiehl N, Müller A, Woitasky N, Akintürk H, Müller M, Weigand MA, Abdallah Y, Kasseckert S, Schreckenberg R, Schlüter KD, Wenzel S: New insights into paracrine mechanisms of human cardiac progenitor cells. Eur J Heart Fail; 2010 Jul;12(7):730-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Cardiac progenitor cells (CPCs) have been shown to promote cardiac regeneration in vivo.
  • Understanding the function of CPCs is essential for further implementation of these cells in the treatment of cardiac diseases.
  • The present study tested the hypothesis that adult CPC exert paracrine effects that lead to an improvement in the functional characteristics of cardiomyocytes.
  • This study also investigated whether aging (we included patients aged between 4 months and 81 years) has any effect on the paracrine mechanisms of CPC.
  • METHODS AND RESULTS: The supernatant of CPC generated both from human and rat hearts-so called 'conditioned cardiosphere medium' improved the contractile behaviour of isolated adult cardiomyocytes in a concentration-dependent manner after incubation for 24 h and increased the SERCA/NCX ratio.
  • The observed positive effects on contractile behaviour were independent of the CPC donors' age.
  • Cytokines released by CPC into the media were detected by cytokine arrays.
  • CONCLUSION: The observed diversity of cytokines released by CPC needs to be further elucidated in detail.
  • Nevertheless, CPC are a promising therapeutic approach in the field of cardiac disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Heart Fail. 2010 Jul;12(7):642-4 [20576832.001]
  • (PMID = 20406797.001).
  • [ISSN] 1879-0844
  • [Journal-full-title] European journal of heart failure
  • [ISO-abbreviation] Eur. J. Heart Fail.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines
  •  go-up   go-down


77. Li FY, Cheng NS, Mao H, Jiang LS, Cheng JQ, Li QS, Munireddy S: Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis. World J Surg; 2009 Oct;33(10):2155-60
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recently, high stone recurrence and biliary restenosis rates in hepatolithiasis patients have been confirmed to be closely related to chronic proliferative cholangitis (CPC).
  • However, the effective management of CPC has not yet been established.
  • METHODS AND RESULTS: A vicious cycle exists between the presence of intrahepatic calculi and CPC: both the stone itself and secondary biliary infection can stimulate persistent hyperplasia in the biliary duct wall, leading to the occurrence of CPC and biliary stricture.
  • The recurrent attacks of CPC will, in turn, facilitate new stone formation via mucoglycoprotein production, or induced biliary stricture and cholestasis.
  • Thus, even when the stone is completely removed and the biliary tract stenosis is corrected, residual CPC will persist and progress, with an underlying risk for postoperative stone recurrence and biliary tract restenosis.
  • Therefore, the perfect hepatolithiasis treatment would target stone removal and correction of the biliary tract stricture, as well as control of postoperative residual CPC.
  • In fact, CPC, the management of which has been traditionally ignored, is the key to breaking this vicious cycle.
  • CONCLUSIONS: Overall, the subsequent treatment of residual CPC after operation or choledochoscopic lithotomy would be helpful to decrease postoperative stone recurrence and the rate of biliary restenosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1998 Sep;28(3):605-12 [9731547.001]
  • [Cites] Surg Today. 1994;24(9):849-51 [7865966.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):328-41 [9164499.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):95-101 [11796004.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1988 Sep;26(9):513-22, 572 [3072167.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6):885-9 [12447303.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1990 Aug;28(8):494-6, 511 [2086117.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):164-5 [16794412.001]
  • [Cites] Korean J Intern Med. 2002 Mar;17(1):57-60 [12014214.001]
  • [Cites] Dig Dis Sci. 1986 Jan;31(1):21-6 [3940820.001]
  • [Cites] AJR Am J Roentgenol. 1997 Dec;169(6):1523-7 [9393156.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):8-12 [12629979.001]
  • [Cites] World J Surg. 2007 Mar;31(3):479-82 [17334864.001]
  • [Cites] Chin Med J (Engl). 1996 Jul;109(7):506-9 [9206093.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1989 Dec;20(4):417-20 [2534303.001]
  • [Cites] World J Surg. 2000 Jun;24(6):712-6 [10773124.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4170-4 [16830367.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Jan-Feb;7(1):36-41 [1543865.001]
  • [Cites] Surgery. 2004 Apr;135(4):386-93 [15041962.001]
  • [Cites] World J Gastroenterol. 2009 Jan 7;15(1):95-101 [19115473.001]
  • [Cites] Vasc Med. 2000;5(2):103-14 [10943587.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):194-7 [7848091.001]
  • [Cites] Jpn J Surg. 1982;12(3):163-70 [7131962.001]
  • [Cites] Am Surg. 2001 May;67(5):442-6 [11379645.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):149-53 [11822950.001]
  • [Cites] Br J Surg. 1992 Jul;79(7):663-6 [1643480.001]
  • [Cites] Clin Infect Dis. 1994 Aug;19(2):279-86 [7986900.001]
  • [Cites] Am J Surg. 1998 Jul;176(1):34-7 [9683129.001]
  • [Cites] J Surg Res. 2005 Sep;128(1):126-31 [16005898.001]
  • [Cites] J Mol Med (Berl). 2001 Dec;79(12):695-706 [11862313.001]
  • [Cites] J Gastroenterol Hepatol. 2006 May;21(5):880-6 [16704540.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):176-82 [14505153.001]
  • [Cites] Chin Med Sci J. 2005 Jun;20(2):123-5 [16075753.001]
  • [Cites] Gastroenterology. 1965 Oct;49(4):343-53 [5831777.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):10-9 [15973096.001]
  • [Cites] Arch Surg. 1999 Mar;134(3):267-73 [10088566.001]
  • [Cites] Hum Pathol. 1992 May;23(5):483-90 [1568745.001]
  • [Cites] HPB Surg. 1995;9(1):37-41 [8857452.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):53-60 [17456835.001]
  • [Cites] J Am Coll Surg. 1999 Aug;189(2):177-82 [10437840.001]
  • [Cites] Surgery. 1991 Apr;109(4):474-80 [2008653.001]
  • [Cites] J Hepatol. 1989 Sep;9(2):141-8 [2809154.001]
  • [Cites] J Surg Res. 2005 Aug;127(2):131-8 [15936771.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Sep;15(9):1071-5 [11059940.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):64-7 [15730922.001]
  • [Cites] Am J Dig Dis. 1968 Jun;13(6):551-7 [5683438.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):318-23 [11231390.001]
  • [Cites] Pharmacogenomics. 2006 Dec;7(8):1185-98 [17184206.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 May;2(2):281-4 [14599985.001]
  • [Cites] Am J Infect Control. 2000 Aug;28(4):298-301 [10926707.001]
  • [Cites] Chin Med J (Engl). 2002 Jan;115(1):62-4 [11930661.001]
  • [Cites] Hum Pathol. 1988 Oct;19(10):1181-6 [3169727.001]
  • [Cites] Methods Mol Med. 2005;106:37-50 [15375311.001]
  • [Cites] J Clin Gastroenterol. 2004 Apr;38(4):364-7 [15087697.001]
  • (PMID = 19641953.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


78. Kai-Chiang Y, Ching-Yao Y, Chang-Chin W, Tzong-Fu K, Feng-Huei L: In vitro study of using calcium phosphate cement as immunoisolative device to enclose insulinoma/agarose microspheres as bioartificial pancreas. Biotechnol Bioeng; 2007 Dec 15;98(6):1288-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the feasibility of using calcium phosphate cement (CPC) as immunoisolative device to enclose insulinoma/agarose microspheres as bioartificial pancreas was evaluated.
  • We fabricated a chamber by CPC and utilized X-ray diffraction, Scanning electron microscope and Mercury intrusion porosimetry to identify the characters of the CPC chamber.
  • The nominal molecular weight cut-off and cytotoxicity of CPC chamber were also evaluated.
  • An insulinoma cell line (RIN-m5F) was chosen as insulin source and encapsulated in agarose microspheres and then enclosed in preformed CPC chamber.
  • Insulin secretion was analyzed by Enzyme-linked immunosorbant assay to evaluate the function of insulinoma enclosed in CPC chamber.
  • Results showed that the CPC chamber was non-cytotoxicity to insulinoma and can block the penetration of molecules which molecular weight larger than 12.4 kDa.
  • Insulinoma inside the CPC chamber can secrete insulin in stable level for 30 days.
  • This study indicated that we may use CPC as immunoisolative material to enclose insulinoma/agarose microspheres as bioartificial pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley Periodicals, Inc.
  • (PMID = 17514757.001).
  • [ISSN] 0006-3592
  • [Journal-full-title] Biotechnology and bioengineering
  • [ISO-abbreviation] Biotechnol. Bioeng.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Insulin; 9012-36-6 / Sepharose; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


79. Bordbar AK, Taheri-Kafrani A, Mousavi SH, Haertlé T: Energetics of the interactions of human serum albumin with cationic surfactant. Arch Biochem Biophys; 2008 Feb 15;470(2):103-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heat capacity changes for interaction of human serum albumin (HSA) and a cationic surfactant-cetylpyridinium chloride (CPC), were studied at conditions close to physiological (50mM HEPES or phosphate buffer, pH 7.4 and 160mM NaCl) carrying out isothermal calorimetric titrations (ITC) at various temperatures (20-40 degrees C).
  • ITC measurements indicated that the small endothermic changes associated with CPC demicellization were temperature independent at these conditions.
  • Surprisingly, important enthalpy changes associated with binding of CPC to HSA were exothermic and temperature independent at lower concentrations (below 0.022mM) of CPC and endothermic and temperature dependent at higher concentrations of CPC.
  • The values of heat capacity changes were obtained for each studied concentration of CPC from the plot of enthalpy changes vs temperature.
  • The obtained results demonstrate the temperature independence of heat capacity changes at entire range of studied CPC concentrations.
  • Both enthalpograms and heat capacity curves indicate the two-step mechanism of HSA folding changes due to its interactions with CPC.
  • The analysis of the results indicates that predominant cooperative unfolding occurs at CPC/HSA molar ratio region between 25 and 30.
  • Such information could not be extracted from thermograms and describes the role of heat capacity as a major thermodynamic quantity giving insight on physical, mechanistic and even atomic-level into how HSA may unfold and interact with CPC.
  • The effect of CPC binding on HSA intrinsic fluorescence, UV-Vis and CD spectra were also examined.
  • Hence, the analysis of spectral data confirms the ITC results about the biphasic mechanism of HSA folding changes induced by CPC.
  • The CD measurement also represents the conservation of considerable secondary structure of HSA due to interaction with CPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068661.001).
  • [ISSN] 1096-0384
  • [Journal-full-title] Archives of biochemistry and biophysics
  • [ISO-abbreviation] Arch. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations; 0 / Serum Albumin; 0 / Surface-Active Agents; CUB7JI0JV3 / Cetylpyridinium
  •  go-up   go-down


80. Lu X, Yang C, Hill R, Yin C, Hollander MC, Fornace AJ Jr, Van Dyke T: Inactivation of gadd45a sensitizes epithelial cancer cells to ionizing radiation in vivo resulting in prolonged survival. Cancer Res; 2008 May 15;68(10):3579-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of gadd45a sensitizes epithelial cancer cells to ionizing radiation in vivo resulting in prolonged survival.
  • Ionizing radiation (IR) therapy is one of the most commonly used treatments for cancer patients.
  • Identifying molecules and mechanisms that sensitize tumor cells to IR provides new potential therapeutic strategies for cancer treatment.
  • In this study, we used two genetically engineered mouse carcinoma models, brain choroid plexus carcinoma (CPC) and prostate, to test the effect of inactivating gadd45a, a DNA damage response p53 target gene, on tumor responses to IR.
  • Effect on survival was assessed in the CPC model and was extended in IR-treated mice with gadd45a deficiency compared with those expressing wild-type gadd45a.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):411-6 [10661348.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8448-54 [16951155.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16602-8 [10747892.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1584-8 [10887152.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):6017-30 [11486039.001]
  • [Cites] Science. 2002 Apr 19;296(5567):530-4 [11964479.001]
  • [Cites] Immunity. 2002 Apr;16(4):499-508 [11970874.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7305-15 [12499274.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):117-29 [12563311.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E22 [14966529.001]
  • [Cites] Mol Cell Biol. 1991 Dec;11(12):5968-76 [1658622.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Cell. 1994 Aug 26;78(4):703-11 [8069917.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):552-7 [7566157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14590-5 [9405657.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):283-92 [9774967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3706-11 [10097101.001]
  • [Cites] Cell. 1999 May 28;97(5):575-86 [10367887.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):176-84 [10508513.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):396-402 [15735649.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4488-500 [15899854.001]
  • [Cites] Cell Cycle. 2005 May;4(5):704-9 [15846075.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10243-54 [16288012.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3705-14 [10779360.001]
  • (PMID = 18483238.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / NIGMS NIH HHS / GM / T32 GM007092-34; United States / NIGMS NIH HHS / GM / GM007092-34; United States / NCI NIH HHS / CA / 5-RO1CA46283; United States / NIGMS NIH HHS / GM / T32 GM007092; United States / NCI NIH HHS / CA / R01 CA046283
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Gadd45a protein, mouse; 0 / Nuclear Proteins
  • [Other-IDs] NLM/ NIHMS112578; NLM/ PMC2693270
  •  go-up   go-down


81. Weir MD, Xu HH: Human bone marrow stem cell-encapsulating calcium phosphate scaffolds for bone repair. Acta Biomater; 2010 Oct;6(10):4118-26
Hazardous Substances Data Bank. ALGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to its injectability and excellent osteoconductivity, calcium phosphate cement (CPC) is highly promising for orthopedic applications.
  • However, a literature search revealed no report on human bone marrow mesenchymal stem cell (hBMSC) encapsulation in CPC for bone tissue engineering.
  • The aim of this study was to encapsulate hBMSCs in alginate hydrogel beads and then incorporate them into CPC, CPC-chitosan and CPC-chitosan-fiber scaffolds.
  • After 21 days, that the percentage of live cells and the cell density of hBMSCs inside CPC-based constructs matched those in alginate without CPC, indicating that the CPC setting reaction did not harm the hBMSCs.
  • The amount of hBMSC-synthesized mineral in CPC-chitosan-fiber matched that in CPC without chitosan and fibers.
  • Hence, adding chitosan and fibers, which reinforced the CPC, did not compromise hBMSC osteodifferentiation and mineral synthesis.
  • In conclusion, hBMSCs were encapsulated in CPC and CPC-chitosan-fiber scaffolds for the first time.
  • These self-setting, hBMSC-encapsulating CPC-based constructs may be promising for bone tissue engineering applications.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALGINIC ACID .
  • Hazardous Substances Data Bank. CALCIUM ALGINATE .
  • Hazardous Substances Data Bank. POTASSIUM ALGINATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Ltd.
  • [Cites] Tissue Eng. 2007 Mar;13(3):493-500 [17362133.001]
  • [Cites] Biotechnol Prog. 2006 Nov-Dec;22(6):1697-701 [17137320.001]
  • [Cites] J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:36-42 [18292355.001]
  • [Cites] J Biomed Mater Res A. 2008 Apr;85(1):218-27 [17688280.001]
  • [Cites] J Dent Res. 2008 Jul;87(7):650-4 [18573985.001]
  • [Cites] Acta Biomater. 2008 Sep;4(5):1465-71 [18445539.001]
  • [Cites] Nat Mater. 2008 Oct;7(10):816-23 [18724374.001]
  • [Cites] Acta Biomater. 2008 Nov;4(6):1904-15 [18571999.001]
  • [Cites] Tissue Eng Part A. 2009 Feb;15(2):243-54 [19193129.001]
  • [Cites] Biomaterials. 2009 May;30(14):2675-82 [19187958.001]
  • [Cites] Tissue Eng Part A. 2009 Jul;15(7):1695-707 [19119921.001]
  • [Cites] Acta Biomater. 2009 Sep;5(7):2752-62 [19357005.001]
  • [Cites] J Dent Res. 2009 Aug;88(8):681-92 [19734453.001]
  • [Cites] J Dent Hyg. 2009 Fall;83(4):173-4 [19909633.001]
  • [Cites] Acta Biomater. 2010 Jan;6(1):218-28 [19563923.001]
  • [Cites] Acta Biomater. 2010 Mar;6(3):876-85 [19835998.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2010 Apr;93(1):93-105 [20091907.001]
  • [Cites] J Biomed Mater Res. 2001 Dec 5;57(3):457-66 [11523041.001]
  • [Cites] Biomaterials. 2002 Jan;23(1):193-202 [11763861.001]
  • [Cites] J Biomed Mater Res. 2002;63(1):1-9 [11787022.001]
  • [Cites] J Biomed Mater Res. 2002 Jul;61(1):47-52 [12001245.001]
  • [Cites] Eur J Pharm Sci. 2003 Jan;18(1):23-30 [12554069.001]
  • [Cites] Biomaterials. 2004 Mar;25(6):1029-37 [14615168.001]
  • [Cites] J Biomed Mater Res A. 2004 Mar 15;68(4):773-82 [14986332.001]
  • [Cites] J Orthop Res. 2004 May;22(3):535-43 [15099632.001]
  • [Cites] Biomacromolecules. 2004 Sep-Oct;5(5):1720-7 [15360280.001]
  • [Cites] Macromol Biosci. 2004 Aug 9;4(8):743-65 [15468269.001]
  • [Cites] J Biomech. 1985;18(5):317-28 [4008502.001]
  • [Cites] Clin Plast Surg. 1992 Jan;19(1):41-58 [1537227.001]
  • [Cites] Clin Mater. 1993;14(1):65-88 [10171998.001]
  • [Cites] Transplantation. 1996 Oct 15;62(7):888-93 [8878379.001]
  • [Cites] Dent Mater J. 1995 Jun;14(1):45-57 [8940545.001]
  • [Cites] Biol Pharm Bull. 1996 Nov;19(11):1518-20 [8951178.001]
  • [Cites] J Cell Biochem. 1997 Feb;64(2):278-94 [9027588.001]
  • [Cites] Ann Periodontol. 1996 Nov;1(1):621-66 [9118274.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 May;85(5):512-6 [9619665.001]
  • [Cites] J Biomed Mater Res. 1998 Winter;43(4):428-32 [9855201.001]
  • [Cites] Biomaterials. 2005 May;26(13):1553-63 [15522757.001]
  • [Cites] Tissue Eng. 2004 Sep-Oct;10(9-10):1480-91 [15588407.001]
  • [Cites] J Biomed Mater Res A. 2005 Dec 15;75(4):966-75 [16123976.001]
  • [Cites] J Biomed Mater Res A. 2006 Jun 1;77(3):487-96 [16482548.001]
  • [Cites] J Control Release. 2006 Jun 28;113(2):102-10 [16740332.001]
  • [Cites] Biomaterials. 2006 Nov;27(32):5480-9 [16857254.001]
  • [Cites] Biomaterials. 2007 Feb;28(6):1071-83 [17123602.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Aug;65(8):1640-7 [17656295.001]
  • (PMID = 20451676.001).
  • [ISSN] 1878-7568
  • [Journal-full-title] Acta biomaterialia
  • [ISO-abbreviation] Acta Biomater
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE014190-07A1; United States / NIDCR NIH HHS / DE / R01 DE014190-07A1S1; United States / NIDCR NIH HHS / DE / R01 DE014190-07A1; United States / NIDCR NIH HHS / DE / R01 DE014190; United States / NIDCR NIH HHS / DE / R01 DE14190; United States / NIDCR NIH HHS / DE / R01 DE17974; United States / NIDCR NIH HHS / DE / R01 DE017974
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alginates; 0 / Biocompatible Materials; 0 / Bone Cements; 0 / Calcium Phosphates; 0 / Hexuronic Acids; 0 / Hydrogels; 8A5D83Q4RW / Glucuronic Acid; 8C3Z4148WZ / alginic acid; 9012-76-4 / Chitosan
  • [Other-IDs] NLM/ NIHMS250252; NLM/ PMC2994102
  •  go-up   go-down


82. Ying ST, Huang WF, Tian LY, Shen XY: [Effects of Pb(NO3)2 and cetylpyridinium chloride on sorption of p-nitrophenol by sediment]. Huan Jing Ke Xue; 2006 Jul;27(7):1373-6
Hazardous Substances Data Bank. P-NITROPHENOL SODIUM SALT .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sorption behavior of p-nitrophenol by sediment in the presence of both cetylpyridinium chloride (CPC) and Pb(NO3)2 were investigated.
  • The concurrence of Pb(NO3)2 inhibited the enhancement of sorption induced by CPC.
  • The removal effect of pnitrophenol from sediment by compounding of CPC and Pb(NO3)2 presented antagonistic effect.
  • At a given concentration of CPC, the antagonistic effect increased with increasing of the initial concentration of Pb(NO3)2.
  • The antagonistic effect was also dependent on CPC concentrations.
  • With the increase of the concentration of CPC, the antagonistic effect decreased gradually.
  • Especially at the higher concentration above CMC, the effect went to be an independent effect just induced by CPC.
  • In addition, the study also indicate that Pb2+ and CPC may not compete for the same adsorption sites.

  • Hazardous Substances Data Bank. 4-NITROPHENOL .
  • Hazardous Substances Data Bank. LEAD NITRATE .
  • Hazardous Substances Data Bank. Lead, elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16881312.001).
  • [ISSN] 0250-3301
  • [Journal-full-title] Huan jing ke xue= Huanjing kexue
  • [ISO-abbreviation] Huan Jing Ke Xue
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nitrates; 0 / Nitrophenols; 0 / Surface-Active Agents; 0 / Water Pollutants, Chemical; 2P299V784P / Lead; 6E5P1699FI / lead nitrate; CUB7JI0JV3 / Cetylpyridinium; Y92ZL45L4R / 4-nitrophenol
  •  go-up   go-down


83. Carusio N, Wangensteen R, Filippelli A, Andriantsitohaina R: Oral administration of polyphenolic compounds from cognac decreases ADP-induced platelet aggregation and reduces chronotropic effect of isoprenaline in rats. Physiol Res; 2008;57(4):517-24
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study sought to evaluate whether consumption of polyphenol extract from Cognac (CPC) modulates platelet activation and cardiovascular reactivity in rats.
  • Male Wistar rats were treated daily for 4 weeks by intra-gastric gavage receiving CPC at 80 mg/kg/day or vehicle (5 % glucose).
  • Oral administration of CPC decreased platelet aggregation induced by ADP but not by collagen.
  • CPC did not affect adhesion to collagen.
  • The chronotropic but not the inotropic response to isoprenaline was reduced without alteration of NO production in hearts from CPC-treated rats.
  • CPC treatment did not affect ex vivo relaxation to acetylcholine nor NO content of rat aorta.
  • CPC did not significantly alter the response to phenylephrine in aorta despite the participation of endothelial vasoconstrictor products.
  • In summary, chronic treatment with CPC has no impact on ex vivo vascular and cardiac reactivity; however, it reduced heart work and platelet aggregation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705676.001).
  • [ISSN] 0862-8408
  • [Journal-full-title] Physiological research
  • [ISO-abbreviation] Physiol Res
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 31C4KY9ESH / Nitric Oxide; 61D2G4IYVH / Adenosine Diphosphate; 9007-34-5 / Collagen; L628TT009W / Isoproterenol
  •  go-up   go-down


84. Sall Diallo A, Sarr M, Mostefai HA, Carusio N, Pricci M, Andriantsitohaina R: Cognac polyphenolic compounds increase bradykinin-induced nitric oxide production in endothelial cells. Physiol Res; 2008;57(6):885-92
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently reported that in vitro Cognac polyphenolic compounds (CPC) induce NO-dependent vasorelaxant effects and stimulate cardiac function.
  • In the present study, we aim to investigate the effect of CPC on both nitric oxide (NO) and superoxide anions (O(2)(-)) production in cultured human endothelial cells.
  • The role and sources of O(2)(-) in the concomitant effect of BK plus CPC were pharmacologically determined.
  • Both, CPC and BK induced an increase in NO production in human endothelial cells.
  • The capacity of CPC plus BK to increase NO signal was blunted by the NO synthase inhibitor, N(G)-nitro-L-arginine methyl ester, and was enhanced in the presence either of superoxide dismutase or catalase.
  • Moreover, CPC plus BK response was greater after inhibition of either NADPH oxidase by apocynin or xanthine oxidase by allopurinol but it was not affected by rotenone.
  • CPC did not affect O(2)(-) level either alone or after its increase upon lipopolysaccharide treatment.
  • Altogether, these data demonstrate that CPC is able to directly increase NO production without affecting O(2)(-) and enhances the BK-induced NO production in human endothelial cells.
  • The data highlight the ability of BK to stimulate not only NADPH oxidase- but also xanthine oxidase-inhibitor sensitive mechanisms that reduce its efficiency in increasing NO either alone or in the presence of CPC.
  • These results bring pharmacological evidence for vascular protection by CPC via its potentiating effect of BK response in terms of endothelial NO release.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18052679.001).
  • [ISSN] 0862-8408
  • [Journal-full-title] Physiological research
  • [ISO-abbreviation] Physiol Res
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Lipopolysaccharides; 0 / Phenols; 0 / Polyphenols; 11062-77-4 / Superoxides; 31C4KY9ESH / Nitric Oxide; EC 1.11.1.6 / Catalase; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.17.3.2 / Xanthine Oxidase; EC 1.6.3.1 / NADPH Oxidase; S8TIM42R2W / Bradykinin
  •  go-up   go-down


85. Purkait MK, Dasgupta S, De S: Precipitation of cetyl (hexadecyl) pyridineum chloride using mono and divalent oxyanions. J Hazard Mater; 2008 Dec 30;160(2-3):502-7
Hazardous Substances Data Bank. POTASSIUM CHROMATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experimental investigations have been carried out to observe the performance of precipitation behavior of potassium permanganate (KMnO4) and potassium dichromate (K2Cr2O7) in cetyl (hexadecyl) pyridineum chloride (CPC) solution.
  • Celik, Langmuir 4 (1988) 1061-1063], the precipitation is found to be caused by interaction of CPC micelles with oxyanions.
  • The counter oxyanions have a strong tendency to bind themselves to the surface of cationic CPC micelles.
  • Therefore, to start precipitation, higher oxyanion concentration is required for higher CPC concentration.
  • The effects of temperature, concentrations of both counter ions and CPC on the precipitation have been studied in detail.
  • It has been observed that at CPC to KMnO4 concentration ratio of 1.0 (concentration of CPC and KMnO4 is 400ppm), the percentage precipitation of CPC is around 99.3 at 30 degrees C.
  • The percent precipitation of CPC decreases to about 94% when temperature increases to 70 degrees C at the same condition.
  • The extent of CPC precipitation increases at the same experimental condition when K2Cr2O7 is used instead of KMnO4.

  • Hazardous Substances Data Bank. POTASSIUM PERMANGANATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417282.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cations, Divalent; 0 / Chromates; 0 / Micelles; 0 / Potassium Compounds; 0 / Solutions; 0 / Surface-Active Agents; 00OT1QX5U4 / Potassium Permanganate; 5P0R38CN2X / potassium chromate(VI); CUB7JI0JV3 / Cetylpyridinium
  •  go-up   go-down


86. St John SJ, Hallagan LD: Psychophysical investigations of cetylpyridinium chloride in rats: its inherent taste and modifying effects on salt taste. Behav Neurosci; 2005 Feb;119(1):265-79
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salts are transduced by at least 2 mechanisms: (a) antagonized by amiloride and (b) antagonized by cetylpyridinium chloride (CPC).
  • The authors report on 4 behavioral experiments in rats that characterize the orosensory properties of CPC itself as well as its effect in suppressing the intensity of NaCl and KCl taste.
  • Experiments 1 and 2 indicated that CPC has a quinine-like taste quality.
  • Experiments 3 and 4 demonstrated that the recognition of KCl, but not NaCl, is modestly reduced by mixture with CPC.
  • However, control experiments call into question the mechanism of the salt suppression of CPC, because both CPC-salt and quinine-salt mixtures had similar effects.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. QUININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 APA.
  • (PMID = 15727531.001).
  • [ISSN] 0735-7044
  • [Journal-full-title] Behavioral neuroscience
  • [ISO-abbreviation] Behav. Neurosci.
  • [Language] eng
  • [Grant] United States / PHS HHS / / DX006886
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Detergents; 451W47IQ8X / Sodium Chloride; A7V27PHC7A / Quinine; CUB7JI0JV3 / Cetylpyridinium
  •  go-up   go-down


87. Popa ER, Harmsen MC, Tio RA, van der Strate BW, Brouwer LA, Schipper M, Koerts J, De Jongste MJ, Hazenberg A, Hendriks M, van Luyn MJ: Circulating CD34+ progenitor cells modulate host angiogenesis and inflammation in vivo. J Mol Cell Cardiol; 2006 Jul;41(1):86-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within the phenotypically and functionally heterogeneous group of circulating progenitor cells (CPC), a subclass of cells with vascular repair potential have been identified.
  • These CPC are detected and isolated based on single or combined expression of CD34, CD133 and VEGFR-2, and referred to as endothelial progenitor cells.
  • Here we asked whether CPC subsets defined by single expression of these markers exhibit functional heterogeneity.
  • As functional parameters, we chose the capacity of CPC to differentiate into endothelial cells.
  • We established an in vivo model in which the intrinsic functional capacity of these human CPC subsets was studied.
  • Human CD34+ CPC, but not CD133+ or VEGFR-2+ CPC, seeded in Matrigel pellets and transplanted subcutaneously in a nude mouse host, contributed little to donor-derived neovascularization.
  • However, host angiogenesis in the Matrigel implant, as demonstrated by the presence of capillaries containing erythrocytes and expressing mouse CD31, was strong in response to implantation of human CD34+ CPC and significantly lower in response to the other two CPC subsets.
  • Moreover, the CD34+ CPC subset was significantly superior to CD133+ CPC and VEGFR-2+ CPC in the recruitment of host monocytes/macrophages.
  • These three CPC populations were further dissected into seven discrete subsets, based on three-parameter flow cytometry analysis of combined expression patterns of CD34, CD133 and VEGFR-2.
  • In conclusion, in our system, CD34+ CPC contribute marginally to neovascularization by differentiation but are potent regulators of the host angiogenic and pro-inflammatory response, suggesting a possible role for these cells in the remodeling of vascular lesions.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780869.001).
  • [ISSN] 0022-2828
  • [Journal-full-title] Journal of molecular and cellular cardiology
  • [ISO-abbreviation] J. Mol. Cell. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Peptides; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


88. Bohnert KA, Chen JS, Clifford DM, Vander Kooi CW, Gould KL: A link between aurora kinase and Clp1/Cdc14 regulation uncovered by the identification of a fission yeast borealin-like protein. Mol Biol Cell; 2009 Aug;20(16):3646-59
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chromosomal passenger complex (CPC) regulates various events in cell division.
  • Together, these four subunits interdependently regulate CPC function, and they are highly conserved among eukaryotes.
  • Here, we isolate a previously uncharacterized S. pombe protein through association with the Cdc14 phosphatase homologue, Clp1/Flp1, and identify it as a Borealin-like member of the CPC.
  • Nbl1 (novel Borealin-like 1) physically associates with known CPC components, affects the kinase activity and stability of the S. pombe Aurora B homologue, Ark1, colocalizes with known CPC subunits during mitosis, and shows sequence similarity to human Borealin.
  • Further analysis of the Clp1-Nbl1 interaction indicates that Clp1 requires CPC activity for proper accumulation at the contractile ring (CR).
  • Consistent with this, we describe negative genetic interactions between mutant alleles of CPC and CR components.
  • Thus, this study characterizes a fission yeast Borealin homologue and reveals a previously unrecognized connection between the CPC and the process of cytokinesis in S. pombe.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):235-44 [11231572.001]
  • [Cites] Nature. 2001 Jun 28;411(6841):1068-73 [11429609.001]
  • [Cites] Genes Cells. 2001 Sep;6(9):743-63 [11554922.001]
  • [Cites] Chromosoma. 2001 Sep;110(5):322-34 [11685532.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4371-84 [11792803.001]
  • [Cites] Genetics. 2002 Feb;160(2):445-56 [11861551.001]
  • [Cites] Mol Biol Cell. 2002 Apr;13(4):1132-43 [11950927.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):143-7 [12161753.001]
  • [Cites] Nature. 2002 Sep 5;419(6902):82-6 [12214236.001]
  • [Cites] Curr Biol. 2002 Dec 10;12(23):2048-54 [12477395.001]
  • [Cites] Curr Biol. 2003 Apr 1;13(7):590-7 [12676091.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):875-87 [12796476.001]
  • [Cites] Mol Biol Cell. 2003 Aug;14(8):3325-41 [12925766.001]
  • [Cites] Science. 2003 Dec 19;302(5653):2120-4 [14605209.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):919-29 [14765109.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2461-8 [15128870.001]
  • [Cites] Methods. 2004 Jul;33(3):239-44 [15157891.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2895-906 [15064354.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):179-91 [15249581.001]
  • [Cites] J Cell Sci. 2004 Aug 1;117(Pt 17):3897-910 [15265986.001]
  • [Cites] Chromosoma. 2004 Nov;113(5):211-22 [15351889.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):10857-64 [2358444.001]
  • [Cites] Chromosoma. 1991 Mar;100(3):139-46 [2040201.001]
  • [Cites] EMBO J. 1991 Nov;10(11):3297-309 [1655416.001]
  • [Cites] Gene. 1993 Jan 15;123(1):127-30 [8422996.001]
  • [Cites] Gene. 1993 Jan 15;123(1):131-6 [8422997.001]
  • [Cites] J Cell Sci. 1993 May;105 ( Pt 1):135-43 [8395535.001]
  • [Cites] Genetics. 1994 Mar;136(3):849-56 [8005439.001]
  • [Cites] J Cell Biol. 1997 Apr 21;137(2):399-416 [9128251.001]
  • [Cites] Curr Biol. 1998 May 21;8(11):611-21 [9635188.001]
  • [Cites] Genetics. 1998 Jul;149(3):1265-75 [9649519.001]
  • [Cites] Trends Cell Biol. 1998 Apr;8(4):144-9 [9695827.001]
  • [Cites] Yeast. 1998 Jul;14(10):943-51 [9717240.001]
  • [Cites] J Cell Biol. 1999 Jul 26;146(2):415-25 [10427094.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):755-62 [15525536.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1378-95 [15647375.001]
  • [Cites] Curr Biol. 2005 Aug 9;15(15):1384-9 [16085490.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9000-15 [16199877.001]
  • [Cites] Mol Biol Cell. 2005 Dec;16(12):5465-79 [16176976.001]
  • [Cites] J Cell Biol. 2005 Dec 5;171(5):773-84 [16330709.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1065-74 [16381814.001]
  • [Cites] Cell. 2006 Apr 7;125(1):85-98 [16615892.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2547-58 [16571674.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):833-7 [16769825.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):841-7 [16823372.001]
  • [Cites] Dev Cell. 2006 Sep;11(3):423-30 [16950131.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1179-91 [17174893.001]
  • [Cites] BMC Cell Biol. 2007;8:5 [17241471.001]
  • [Cites] Mol Biol Cell. 2007 May;18(5):1657-69 [17301288.001]
  • [Cites] J Cell Biol. 2007 Jun 18;177(6):981-93 [17562791.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):798-812 [17848966.001]
  • [Cites] Mol Biol Cell. 2007 Oct;18(10):3820-34 [17652458.001]
  • [Cites] Cell. 2007 Oct 19;131(2):271-85 [17956729.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):35018-23 [17881355.001]
  • [Cites] Proteins. 2008 Feb 15;70(3):611-25 [17876813.001]
  • [Cites] Cell. 2008 Jan 25;132(2):233-46 [18243099.001]
  • [Cites] J Cell Biol. 2008 Apr 7;181(1):79-88 [18378776.001]
  • [Cites] Biochem Soc Trans. 2008 Jun;36(Pt 3):367-70 [18481960.001]
  • [Cites] Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W197-201 [18463136.001]
  • [Cites] J Cell Biol. 2008 Oct 20;183(2):279-96 [18936249.001]
  • [Cites] Curr Biol. 2008 Oct 28;18(20):1594-9 [18951025.001]
  • [Cites] Curr Opin Cell Biol. 2008 Dec;20(6):661-8 [18845253.001]
  • [Cites] J Cell Biol. 2009 Jan 12;184(1):113-27 [19139265.001]
  • [Cites] Cell. 2009 Feb 6;136(3):473-84 [19203582.001]
  • [Cites] Mol Biol Cell. 2009 Mar;20(6):1772-84 [19158380.001]
  • [Cites] Nat Cell Biol. 2009 Apr;11(4):477-83 [19270692.001]
  • [Cites] Biochemistry. 2009 Feb 17;48(6):1156-61 [19146389.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5249-54 [10805785.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):E3-6 [11146636.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):27-40 [11149918.001]
  • (PMID = 19570910.001).
  • [ISSN] 1939-4586
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / F32 GM076897; United States / NCI NIH HHS / CA / T32 CA009582; United States / NCRR NIH HHS / RR / P20 RR020171; United States / NCI NIH HHS / CA / T32 CA119925; United States / NCI NIH HHS / CA / T32-CA119925-01A2; United States / NIGMS NIH HHS / GM / F32-GM076897; United States / NCRR NIH HHS / RR / P20RR20171; United States / NCI NIH HHS / CA / T32-CA09582; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDCA8 protein, human; 0 / Cell Cycle Proteins; 0 / Multiprotein Complexes; 0 / Nbl1 protein, S pombe; 0 / Protein Subunits; 0 / Recombinant Fusion Proteins; 0 / Schizosaccharomyces pombe Proteins; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / ark1 protein, S pombe; EC 3.1.3.16 / CDC14 protein, S pombe; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.48 / Clp1 protein, S. pombe; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC2777925
  •  go-up   go-down


89. Ahonen LJ, Kukkonen AM, Pouwels J, Bolton MA, Jingle CD, Stukenberg PT, Kallio MJ: Perturbation of Incenp function impedes anaphase chromatid movements and chromosomal passenger protein flux at centromeres. Chromosoma; 2009 Feb;118(1):71-84
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incenp is an essential mitotic protein that, together with Aurora B, Survivin, and Borealin, forms the core of the chromosomal passenger protein complex (CPC).
  • The CPC regulates various mitotic processes and functions to maintain genomic stability.
  • The proper subcellular localization of the CPC and its full catalytic activity require the presence of each core subunit in the complex.
  • We have investigated the mitotic tasks of the CPC using a function blocking antibody against Incenp microinjected into cells at different mitotic phases.
  • This method allowed temporal analysis of CPC functions without perturbation of complex assembly or activity prior to injection.
  • In these cells, the loss of centromeric CPC turnover is accompanied by forced mitotic exit without the execution of cytokinesis.
  • In summary, our data uncovers new mitotic roles for the CPC in anaphase and proposes that CPC turnover at centromeres modulates spindle assembly checkpoint signaling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Jan;11(1):241-53 [10637305.001]
  • [Cites] Curr Biol. 2000 Sep 7;10(17):1075-8 [10996078.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1172-81 [11050385.001]
  • [Cites] J Cell Biol. 2001 Feb 19;152(4):669-82 [11266459.001]
  • [Cites] J Cell Biol. 2001 May 14;153(4):865-80 [11352945.001]
  • [Cites] Curr Biol. 2001 Jun 5;11(11):886-90 [11516652.001]
  • [Cites] Curr Biol. 2001 Dec 11;11(24):R1001-4 [11747833.001]
  • [Cites] Mol Biol Cell. 2002 Apr;13(4):1099-108 [11950924.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):78-83 [16327780.001]
  • [Cites] Mol Biol Cell. 2006 Jun;17(6):2547-58 [16571674.001]
  • [Cites] J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75 [16912073.001]
  • [Cites] Curr Biol. 2006 Sep 5;16(17):1711-8 [16950108.001]
  • [Cites] Cell. 2006 Dec 1;127(5):969-82 [17129782.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):379-93 [17426725.001]
  • [Cites] Cell Cycle. 2007 Aug 1;6(15):1878-85 [17671419.001]
  • [Cites] Mol Biol Cell. 2007 Sep;18(9):3264-76 [17567953.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):798-812 [17848966.001]
  • [Cites] Cell. 2007 Oct 19;131(2):271-85 [17956729.001]
  • [Cites] Cell Cycle. 2007 Oct 15;6(20):2549-53 [17726378.001]
  • [Cites] Science. 2008 Jan 25;319(5862):469-72 [18218899.001]
  • [Cites] Curr Biol. 2002 Jun 4;12(11):900-5 [12062053.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27577-80 [12048181.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):841-7 [12196507.001]
  • [Cites] Mol Biol Cell. 2002 Sep;13(9):3064-77 [12221116.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):45-53 [12370248.001]
  • [Cites] Cell. 2003 Apr 4;113(1):127-37 [12679040.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):281-94 [12707311.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):267-80 [12719470.001]
  • [Cites] EMBO J. 2003 Jun 16;22(12):2934-47 [12805209.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2987-98 [12783991.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):451-64 [12884918.001]
  • [Cites] Mol Biol Cell. 2003 Aug;14(8):3325-41 [12925766.001]
  • [Cites] Mol Biol Cell. 2004 Jan;15(1):219-33 [14528012.001]
  • [Cites] Curr Biol. 2004 Feb 17;14(4):273-86 [14972678.001]
  • [Cites] Nat Med. 2004 Mar;10(3):262-7 [14981513.001]
  • [Cites] Trends Cell Biol. 2004 Apr;14(4):194-205 [15066637.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):942-52 [15182667.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):953-64 [15182668.001]
  • [Cites] Methods Mol Biol. 2004;280:83-98 [15187250.001]
  • [Cites] Cell Cycle. 2004 Jun;3(6):707-10 [15153812.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4033-42 [15280424.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):2053-67 [3316246.001]
  • [Cites] J Cell Biol. 1998 Mar 9;140(5):991-1002 [9490714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15938-43 [15522967.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1418-26 [15483398.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1305-18 [15616188.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):778-86 [15854913.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):379-91 [15866179.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):576-82 [16233975.001]
  • (PMID = 18784935.001).
  • [ISSN] 1432-0886
  • [Journal-full-title] Chromosoma
  • [ISO-abbreviation] Chromosoma
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM063045; United States / NIGMS NIH HHS / GM / R01 GM081576; United States / NIGMS NIH HHS / GM / R01GM063045-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / INCENP protein, Xenopus; 0 / Xenopus Proteins; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS391053; NLM/ PMC3442196
  •  go-up   go-down


90. Pastorello A, Constantino-Casas F, Archer J: Choroid plexus carcinoma cells in the cerebrospinal fluid of a Staffordshire Bull Terrier. Vet Clin Pathol; 2010 Dec;39(4):505-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus carcinoma cells in the cerebrospinal fluid of a Staffordshire Bull Terrier.
  • The appearance was highly suspicious of a malignant epithelial neoplasm.
  • The dog was euthanized and on postmortem examination an asymmetrical nonencapsulated cerebellar mass was found within the choroid plexus of the fourth ventricle with local extension into the cerebellopontine angle.
  • The diagnosis was choroid plexus carcinoma.
  • The finding of clusters of choroid plexus epithelial cells in the CSF demonstrates the value of utilizing a relatively noninvasive diagnostic technique for diagnosis of choroid plexus tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 American Society for Veterinary Clinical Pathology.
  • (PMID = 21070306.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Ikeda A, Shiotani A, Mori Y, Fujimine T, Tomifuji M, Takaoka T, Kameyama K, Ogawa K: Suitability of calcium phosphate cement for injection laryngoplasty in rabbits. ORL J Otorhinolaryngol Relat Spec; 2006;68(2):103-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcium phosphate cement (CPC) consists of powder and liquid, which become an injectable paste after mixing, self-hardening and recrystallizing to calcium hydroxylapatite (CaHA) after injection into a living body.
  • In this study, we investigated the suitability of CPC as an injectable material for injection laryngoplasty using rabbits.
  • All rabbits underwent left recurrent laryngeal nerve section and injection laryngoplasty with CPC.
  • At 7 days, scanning electron microscopic findings revealed that complete recrystallization from CPC to CaHA was achieved in the larynx.
  • At 1, 3, and 6 months, injected CPC stayed in the paraglottic space and did not migrate, and the average remaining CPC volume percentage was 91.7%.
  • Focal foreign body reaction to injected CPC was almost the same as that of autologous fat for all time periods observed.
  • These results indicated that CPC appears to be biocompatible, nonabsorbable, nonmigratory, and suitable for injection laryngoplasty.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16446556.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Calcium Phosphates; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


92. Nakanishi C, Yamagishi M, Yamahara K, Hagino I, Mori H, Sawa Y, Yagihara T, Kitamura S, Nagaya N: Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun; 2008 Sep 12;374(1):11-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports have suggested that cardiac progenitor cells (CPC) reside in the heart.
  • In this study, we investigated whether MSC had paracrine effects on CPC in vitro.
  • CPC were isolated from the neonatal rat heart using an explant method.
  • MSC-derived conditioned medium promoted proliferation of CPC and inhibited apoptosis of CPC induced by hypoxia and serum starvation.
  • Chemotaxis chamber assay demonstrated that MSC-derived conditioned medium enhanced migration of CPC.
  • Furthermore, MSC-derived conditioned medium upregulated expression of cardiomyocyte-related genes in CPC such as beta-myosin heavy chain (beta-MHC) and atrial natriuretic peptide (ANP).
  • In conclusion, MSC-derived conditioned medium had protective effects on CPC and enhanced their migration and differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586003.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 85637-73-6 / Atrial Natriuretic Factor; EC 3.6.1.- / Ventricular Myosins
  •  go-up   go-down


93. Julien M, Khairoun I, LeGeros RZ, Delplace S, Pilet P, Weiss P, Daculsi G, Bouler JM, Guicheux J: Physico-chemical-mechanical and in vitro biological properties of calcium phosphate cements with doped amorphous calcium phosphates. Biomaterials; 2007 Feb;28(6):956-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcium phosphate cements (CPCs) are successfully used as bone substitutes in dentistry and orthopaedic applications.
  • This study investigated the physico-chemical-mechanical properties of and in vitro biological properties (cell response) of CPCs prepared with amorphous calcium carbonate phosphate (ACCP) doped with magnesium (ACCP-Mg), zinc (ACCp-Zn) or fluoride (ACCP-F) ions.
  • The experimental CPC consisted of alpha-TCP, doped ACCP, and MPCM powders as matrix and biphasic calcium phosphate (BCP) granules.
  • Cements with ACCP-F (F-CPC) had shorter setting times and greater compressive strength compared to cements with ACCP-Mg (Mg-CPC) or ACCP-Zn (Zn-CPC).
  • Scanning electron microscopy (SEM) showed that crystals set on Mg-CPC and Zn-CPC were smaller compared to those on F-CPC.
  • The total porosity of Mg-CPC was greater compared to Zn-CPC or F-CPC.
  • Osteoblast-like cells, MC3T3-E1, remained viable and maintained their ability to express alkaline phosphatase in contact with the CPCs with doped ACCPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123598.001).
  • [ISSN] 0142-9612
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Cements; 0 / Calcium Phosphates; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


94. Cui G, Li J, Lei W, Bi L, Tang P, Liang Y, Tao S, Wang Y: The mechanical and biological properties of an injectable calcium phosphate cement-fibrin glue composite for bone regeneration. J Biomed Mater Res B Appl Biomater; 2010 Feb;92(2):377-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcium phosphate cement (CPC) that can be injected to form a scaffold in situ has promise for the repair of bone defects.
  • However, its low-strength limits the CPC to non-stress-bearing repairs.
  • Fibrin glue (FG) with good sticking property and biocompatibility is possible used to reinforce the CPC.
  • The objective of this study was to investigate the effects of FG on the mechanical and biological properties of CPC in an injectable CPC-FG composite.
  • The initial setting time of this CPC-FG was delayed compared with the CPC control at different powder/liquid (P/L) mass ratio (p > 0.05).
  • At a P/L of 5, the strength was (38.41 +/- 4.32) MPa for the CPC-FG, much higher than (27.42 +/- 2.85) MPa for the CPC alone (p < 0.05).
  • SEM showed bone marrow stromal cells (BMSCs) with healthy spreading and anchored on the CPC-FG composite.
  • After 14 days, the alkaline phosphatase (ALP) activity was (538 +/- 33) for the BMSCs on the CPC-FG and (517 +/- 27) for the BMSCs on the CPC alone.
  • The results demonstrate that this stronger CPC-FG scaffold may be useful for stem cell-based bone regeneration in moderate load-bearing orthopedic applications.
  • [MeSH-minor] Alkaline Phosphatase / metabolism. Animals. Bone Marrow Cells / drug effects. Cell Differentiation. Cell Proliferation. Cells, Cultured. Collagen Type I / metabolism. Compressive Strength. DNA / analysis. DNA / biosynthesis. Female. Immunohistochemistry. Materials Testing. Microscopy, Electron, Scanning. Needles. Rabbits. Stromal Cells / drug effects. Tissue Scaffolds

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19904823.001).
  • [ISSN] 1552-4981
  • [Journal-full-title] Journal of biomedical materials research. Part B, Applied biomaterials
  • [ISO-abbreviation] J. Biomed. Mater. Res. Part B Appl. Biomater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements; 0 / Calcium Phosphates; 0 / Collagen Type I; 0 / Fibrin Tissue Adhesive; 9007-49-2 / DNA; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


95. Edlind MP, Smith WL, Edlind TD: Effects of cetylpyridinium chloride resistance and treatment on fluconazole activity versus Candida albicans. Antimicrob Agents Chemother; 2005 Feb;49(2):843-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mouthwash antiseptic cetylpyridinium chloride (CPC) has potent activity against Candida albicans; however, two of five azole-resistant strains showed reduced CPC susceptibility.
  • To further examine the potential for cross-resistance, CPC-resistant mutants were selected in vitro and their fluconazole susceptibility was tested.
  • With CPC-fluconazole combinations, both antagonism and synergism were observed, which can be explained, in part, by CDR1-CDR2 multidrug transporter upregulation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antimicrob Chemother. 2002 Jan;49(1):11-2 [11751760.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Oct;45(10):2676-84 [11557454.001]
  • [Cites] J Antimicrob Chemother. 2002 Apr;49(4):597-9 [11909832.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jun;46(6):1704-13 [12019079.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3532-9 [12384361.001]
  • [Cites] Clin Microbiol Rev. 2003 Apr;16(2):189-208 [12692093.001]
  • [Cites] J Clin Microbiol. 1976 Mar;3(3):272-6 [773957.001]
  • [Cites] Microbios. 1993;74(299):111-20 [8361392.001]
  • [Cites] Int J Prosthodont. 1995 Sep-Oct;8(5):486-9 [8595107.001]
  • [Cites] Microbiology. 1997 Feb;143 ( Pt 2):405-16 [9043118.001]
  • [Cites] J Periodontol. 1997 Aug;68(8):729-33 [9287062.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Jan;42(1):129-34 [9449272.001]
  • [Cites] J Dent Hyg. 1996 Jul-Aug;70(4):161-5 [9470563.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):147-79 [9880479.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Jan;87(1):44-9 [9927079.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Aug;43(8):1968-74 [10428921.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Dec;43(12):3042-3 [10651623.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Feb;45(2):428-32 [11158736.001]
  • [Cites] Lancet Infect Dis. 2002 Feb;2(2):73-85 [11901654.001]
  • (PMID = 15673785.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI047718; United States / NIAID NIH HHS / AI / AI46768; United States / NIAID NIH HHS / AI / AI47718
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Antifungal Agents; 0 / CDR1 protein, Candida albicans; 0 / Fungal Proteins; 0 / Membrane Transport Proteins; 0 / Mouthwashes; 8VZV102JFY / Fluconazole; CUB7JI0JV3 / Cetylpyridinium
  • [Other-IDs] NLM/ PMC547338
  •  go-up   go-down


96. Breynaert E, Maes A: Column precipitation chromatography: an approach to quantitative analysis of eigencolloids. Anal Chem; 2005 Aug 1;77(15):5048-54
Hazardous Substances Data Bank. Nitrogen, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new column precipitation chromatography (CPC) technique, capable of quantitatively measuring technetium eigencolloids in aqueous solutions, is presented.
  • The CPC technique is based on the destabilization and precipitation of eigencolloids by polycations in a confined matrix.
  • Tc(IV) colloids can be quantitatively determined from their precipitation onto the CPC column (separation step) and their subsequent elution upon oxidation to pertechnetate by peroxide (elution step).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053321.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colloids; N762921K75 / Nitrogen
  •  go-up   go-down


97. Brubaker LM, Bullitt E, Yin C, Van Dyke T, Lin W: Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice. Cancer Res; 2005 Sep 15;65(18):8218-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven TgT121;p53+/- mice, which invariably develop choroid plexus carcinoma (CPC), and nine age-matched healthy controls were imaged using T1, T2, and a high-resolution three-dimensional time-of-flight MRA sequences at 3 T.
  • Although the spatial resolution of MRA prohibits visualization of capillaries, a high density of intratumor blood vessels was visualized in CPC mice.
  • A significant increase in terminal branch count and vessel count, but not average vessel radius, was observed in CPCs when compared with normal controls.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IEEE Trans Med Imaging. 1999 Aug;18(8):712-21 [10534053.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):6017-30 [11486039.001]
  • [Cites] Korean J Radiol. 2001 Jan-Mar;2(1):1-7 [11752962.001]
  • [Cites] Magn Reson Med. 2002 Feb;47(2):305-13 [11810674.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):783-9 [12185064.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] Neuroradiology. 2003 Apr;45(4):205-11 [12687302.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):501-23 [12687908.001]
  • [Cites] Magn Reson Med. 2003 May;49(5):848-55 [12704767.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:179-92 [12795055.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] Cancer Treat Res. 2004;117:97-114 [15015554.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):139-45 [15018898.001]
  • [Cites] Cancer Cell. 2004 May;5(5):443-53 [15144952.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8662-70 [15367684.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6563-70 [15374969.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Cell. 1994 Aug 26;78(4):703-11 [8069917.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1294-300 [9102216.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • (PMID = 16166297.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NCI NIH HHS / CA / P30-CA-16086; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NCI NIH HHS / CA / U01 CA84314; United States / NCI NIH HHS / CA / U01 CA084314; United States / NCRR NIH HHS / RR / S10 RR017212
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS53785; NLM/ PMC2430271
  •  go-up   go-down


98. Chiu HF, Yang SP, Kuo YL, Lai YS, Chou TC: Mechanisms involved in the antiplatelet effect of C-phycocyanin. Br J Nutr; 2006 Feb;95(2):435-40
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms involved in the antiplatelet effect of C-phycocyanin.
  • C-phycocyanin (cpc), a biliprotein isolated from Spirulina platensis, has been reported to exert many therapeutic and nutritional values.
  • In the present study, we examined whether cpc has an antiplatelet activity in vitro and further investigated the possible anti-aggregatory mechanisms involved.
  • Our results showed that preincubation of cpc (1-50 microg/ml) with rabbit washed platelets dose-dependently inhibited the platelet aggregation induced by collagen (10 microg/ml) or arachidonic acid (100 microm), with an IC50 of about 10 microg/ml.
  • Furthermore, the thromboxane B2 formation caused by collagen or arachidonic acid was significantly inhibited by cpc due to suppression of cyclooxygenase and thromboxane synthase activity.
  • Similarly, the rise of platelet intracellular calcium level stimulated by arachidonic acid and collagen-induced platelet membrane surface glycoprotein IIb/IIIa expression were also attenuated by cpc.
  • In addition, cpc itself significantly increased the platelet membrane fluidity and the cyclic AMP level through inhibiting cyclic AMP phosphodiesterase activity.
  • These findings strongly demonstrate that cpc is an inhibitor of platelet aggregation, which may be associated with mechanisms including inhibition of thromboxane A2 formation, intracellular calcium mobilization and platelet surface glycoprotein IIb/IIIa expression accompanied by increasing cyclic AMP formation and platelet membrane fluidity.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469164.001).
  • [ISSN] 0007-1145
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; 0 / Platelet Glycoprotein GPIIb-IIIa Complex; 11016-15-2 / Phycocyanin; 54397-85-2 / Thromboxane B2; E0399OZS9N / Cyclic AMP; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 5.3.99.5 / Thromboxane-A Synthase; H2D2X058MU / Cyclic GMP; SY7Q814VUP / Calcium
  •  go-up   go-down


99. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CV, American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, Society of Chest Pain Centers: Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation; 2005 May 24;111(20):2699-710
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers.
  • In the United States each year, >5.3 million patients present to emergency departments with chest discomfort and related symptoms.
  • This update of the 2002 American College of Cardiology/American Heart Association Guidelines for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction (UA/NSTEMI) provides an evidence-based approach to the diagnosis and treatment of these patients in the emergency department, in-hospital, and after hospital discharge.


100. Koyanagi M, Haendeler J, Badorff C, Brandes RP, Hoffmann J, Pandur P, Zeiher AM, Kühl M, Dimmeler S: Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells. J Biol Chem; 2005 Apr 29;280(17):16838-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human endothelial circulating progenitor cells (CPCs) can differentiate to cardiomyogenic cells during co-culture with neonatal rat cardiomyocytes.
  • Here, we elucidated the effect of Wnts on differentiation of CPCs to cardiomyogenic cells.
  • CPCs from peripheral blood mononuclear cells were isolated from healthy volunteers and co-cultured with neonatal rat cardiomyocytes.
  • Supplementation of co-cultures with Wnt11-conditioned medium significantly enhanced the differentiation of CPCs to cardiomyocytes (1.7+/-0.3-fold), whereas Wnt3A-conditioned medium showed no effect.
  • Because Wnts inhibit glycogen synthase kinase-3beta, we further determined whether the glycogen synthase kinase-3beta inhibitor LiCl also enhanced cardiac differentiation of CPCs.
  • However, LiCl (10 mM) did not affect CPC differentiation.
  • Moreover, the PKC inhibitors bisindolylmaleimide I and III significantly blocked differentiation of CPCs to cardiomyocytes.
  • PKC activation by phorbol 12-myristate 13-acetate significantly increased CPC differentiation to a similar extent as compared with Wnt11-conditioned medium.
  • Our data demonstrate that Wnt11, but not Wnt3A, augments cardiomyogenic differentiation of human CPCs.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. LITHIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701629.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Wnt Proteins; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 3.6.4.1 / Myosin Heavy Chains; G4962QA067 / Lithium Chloride
  •  go-up   go-down






Advertisement